<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><title>Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects - Shaw - 2009 - Annals of Neurology - Wiley Online Library</title><meta name="robots" content="noarchive" /><meta http-equiv="X-UA-Compatible" content="IE=EmulateIE7" /><link rel="stylesheet" type="text/css" media="screen,print" href="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/css/importAll.css" /><link rel="stylesheet" type="text/css" media="print" href="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/css/print.css" /><!--[if IE 6]>
	   <link rel="stylesheet" href="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/css/ie6.css" type="text/css" media="screen,print" />
	   <link rel="stylesheet" href="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/css/simpleForm_ie6.css" type="text/css" media="screen,print" />
    <![endif]--><!--[if IE 7]>
	   <link rel="stylesheet" href="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/css/ie7.css" type="text/css" media="screen" />
	   <link rel="stylesheet" href="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/css/simpleForm_ie7.css" type="text/css" media="screen,print" />
    <![endif]--><script type="text/javascript" xml:space="preserve">
        document.documentElement.className = "js_en";
    </script><link rel="stylesheet" type="text/css" media="screen,print" href="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/css/fullText.css" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_doi" content="10.1002/ana.21610" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_abstract_html_url" content="http://onlinelibrary.wiley.com.proxy.library.emory.edu/doi/10.1002/ana.21610/abstract" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_pdf_url" content="http://onlinelibrary.wiley.com.proxy.library.emory.edu/doi/10.1002/ana.21610/pdf" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_fulltext_html_url" content="http://onlinelibrary.wiley.com.proxy.library.emory.edu/doi/10.1002/ana.21610/full" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_volume" content="65" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_issue" content="4" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_firstpage" content="403" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_lastpage" content="413" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_journal_title" content="Annals of Neurology" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_publisher" content="Wiley Subscription Services, Inc., A Wiley Company" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_issn" content="1531-8249" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_authors" content="Shaw, Leslie M.; Vanderstichele, Hugo; Knapik&#x2010;Czajka, Malgorzata; Clark, Christopher M.; Aisen, Paul S.; Petersen, Ronald C.; Blennow, Kaj; Soares, Holly; Simon, Adam; Lewczuk, Piotr; Dean, Robert; Siemers, Eric; Potter, William; Lee, Virginia M.&#x2010;Y.; Trojanowski, John Q." /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_title" content="Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_online_date" content="2009/03/18" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_language" content="en" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_date" content="2009/04/01" /><script type="text/javascript" xml:space="preserve">
            function RightslinkPopUp(url)
            {      
                 window.open(encodeURI(url),"Rightslink","location=no,toolbar=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,width=650,height=550");
            } 
        </script></head><body><div id="skip"><a href="#content" shape="rect">Skip to Main Content</a></div><div id="leftBorder">         <div id="rightBorder">   <div id="leaderBoard">     <script language="JavaScript" src="http://ad.uk.doubleclick.net/adj/wly.neurology_000086/annls-neuro_ANA;tile=1;sz=728x90;doi=10.1002/ana.21610;ord=535599965?" type="text/javascript" xml:space="preserve">
    </script>      <noscript><a href="http://ad.uk.doubleclick.net/jump/wly.neurology_000086/annls-neuro_ANA;tile=1;sz=728x90;doi=10.1002/ana.21610;ord=535599965?" target="_blank" shape="rect">
            <img src="http://ad.uk.doubleclick.net/ad/wly.neurology_000086/annls-neuro_ANA;tile=1;sz=728x90;doi=10.1002/ana.21610;ord=535599965?" border="0" alt="" />

        </a></noscript> </div><div id="header"> <div id="globalMenu">     <a href="/" title="return to home page" shape="rect"><img src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/images/siteLogo.gif" alt="Wiley Online Library" id="siteLogo" /></a>     <p>         <a href="/" id="home" shape="rect">Home</a>         <a href="http://onlinelibrary.custhelp.com" id="help" shape="rect">Help</a>     </p>     <div>         <ul><li><a href="/browse/publications" shape="rect">PUBLICATIONS</a></li><li><a href="/browse/subjects" shape="rect">BROWSE BY SUBJECT</a></li><li><a href="http://olabout.wiley.com.proxy.library.emory.edu/WileyCDA/Section/id-390229.html" shape="rect">RESOURCES</a></li><li><a href="http://olabout.wiley.com.proxy.library.emory.edu/WileyCDA/Section/id-390001.html" shape="rect">ABOUT US</a></li></ul>     </div> </div><div id="coBranding"> </div>              <div id="login">             <form method="post" action="/j_spring_security_check" id="loginForm" enctype="application/x-www-form-urlencoded"><fieldset>                     <legend>LOGIN</legend>                     <div id="loginInFormInner">                      <label id="emailLabel" for="loginEmail" class="hide">Enter e-mail address</label>                      <input type="text" name="j_username" id="loginEmail" value="" />                      <div>                          <label id="passwordLabel" for="loginPassword" class="hide">Enter password</label>                          <input type="password" id="loginPassword" value="" name="j_password" />                          <input name="submit" id="loginSubmit" type="image" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/images/loginSubmit.png" value="Go" alt="Login" />                      </div>                          <input type="checkbox" name="_spring_security_remember_me" id="loginRememberMe" checked="checked" />                      <label for="loginRememberMe">REMEMBER ME</label>                     </div>                 </fieldset></form>             <ul id="loginOptions"><li><a href="/user-registration" title="NOT REGISTERED" shape="rect">NOT REGISTERED ?</a></li><li><a href="/user/forgottenpassword" id="forgottenPassword" title="FORGOTTEN PASSWORD ?" shape="rect">FORGOTTEN PASSWORD ?</a></li><li><a href="/login-options" title="INSTITUTIONAL LOGIN" shape="rect">INSTITUTIONAL LOGIN &gt;</a></li></ul>         </div>      </div> <div id="breadcrumb"></div>  <div id="pageNavAndTools">            <div class="menuGroup">     <h2>JOURNAL TOOLS</h2>     <ul class="titleTools"><li>                             <a href="/getEmailAlert?id=10.1002%2F%28ISSN%291531-8249&amp;originUrl=%2Fdoi%2F10.1002%2Fana.21610%2Ffull" class="getEmailAlerts" shape="rect">Get New Content Alerts</a>         </li><li>             <a class="rss" href="/rss/journal/10.1002/(ISSN)1531-8249" shape="rect">Get RSS feed</a>         </li><li>                 <a href="/saveTitle?id=10.1002%2F%28ISSN%291531-8249&amp;type=JOURNAL&amp;originUrl=%2Fdoi%2F10.1002%2Fana.21610%2Ffull" class="saveToProfile" shape="rect">Save to My Profile</a>         </li><li>                 <a href="/doi/10.1002/ana.v67:1/issuetoc" class="getSampleCopy" shape="rect">Get Sample Copy</a>             </li></ul> </div>             <div class="menuGroup">  <h2>JOURNAL MENU</h2>  <ul><li><a href="/journal/10.1002/(ISSN)1531-8249" title="Journal Home" shape="rect">Journal Home</a></li></ul> </div> <div class="menuGroup">     <h3>FIND ISSUES</h3>     <ul><li><a href="/journal/10.1002/(ISSN)1531-8249/currentissue" title="Current Issue" id="currentIssueLink" shape="rect">Current Issue</a></li><li><a href="/journal/10.1002/(ISSN)1531-8249/issues" title="All Issues" shape="rect">All Issues</a></li></ul> </div>                    <div class="menuGroup">         <h3>FIND ARTICLES</h3>         <ul><li><a href="/journal/10.1002/(ISSN)1531-8249/earlyview" title="Early View" id="earlyViewLink" shape="rect">Early View</a></li><li><a href="/journal/10.1002/(ISSN)1531-8249/accepted" title="Accepted Articles" id="acceptedArticlesLink" shape="rect">Accepted Articles</a></li></ul>     </div>                  <div class="menuGroup">         <h3>GET ACCESS</h3>          <ul><li>                 <a href="http://ordering.onlinelibrary.wiley.com.proxy.library.emory.edu/subs.asp?ref=1531-8249&amp;doi=10.1002/(ISSN)1531-8249" title="Subscribe / Renew" shape="rect">Subscribe / Renew</a>             </li></ul>     </div>                  <div class="menuGroup">         <h3>FOR CONTRIBUTORS</h3>         <ul><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1002/(ISSN)1531-8249/homepage/ForAuthors.html" title="Author Guidelines" shape="rect">Author Guidelines</a></li></ul>     </div>                  <div class="menuGroup">         <h3>ABOUT THIS JOURNAL</h3>         <ul><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1002/(ISSN)1531-8249/homepage/Society.html" title="Society Information" shape="rect">Society Information</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1002/(ISSN)1531-8249/homepage/News.html" title="News" shape="rect">News</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1002/(ISSN)1531-8249/homepage/ProductInformation.html" title="Overview" shape="rect">Overview</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1002/(ISSN)1531-8249/homepage/EditorialBoard.html" title="Editorial Board" shape="rect">Editorial Board</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1002/(ISSN)1531-8249/homepage/Advertise.html" title="Advertise" shape="rect">Advertise</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1002/(ISSN)1531-8249/homepage/Contact.html" title="Contact" shape="rect">Contact</a></li></ul>     </div>                  <div class="menuGroup">         <h2>SPECIAL FEATURES</h2>         <ul><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1002/(ISSN)1531-8249/homepage/conflict_of_interest.htm" title="Conflict of Interest" shape="rect">Conflict of Interest</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1002/(ISSN)1531-8249/homepage/policy_on_clinical_trials.htm" title="Policy on Clinical Trials" shape="rect">Policy on Clinical Trials</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1002/(ISSN)1531-8249/homepage/professional_opportunities.htm" title="Professional Opportunities" shape="rect">Professional Opportunities</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com.proxy.library.emory.edu/doi/10.1002/ana.20811/pdf" title="Editorial Mission and Scope" shape="rect">Editorial Mission and Scope</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com.proxy.library.emory.edu/doi/10.1002/ana.21150/pdf" title="Peer Review Policy" shape="rect">Peer Review Policy</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com.proxy.library.emory.edu/doi/10.1002/ana.21248/pdf" title="Policy on Genetics Research" shape="rect">Policy on Genetics Research</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com.proxy.library.emory.edu/doi/10.1002/ana.21300/pdf" title="Policy on Epidemiology Research" shape="rect">Policy on Epidemiology Research</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com.proxy.library.emory.edu/journal/10.1002/(ISSN)1531-8249/ed_policy.htm" title="Policy on Basic Neuroscience Research" shape="rect">Policy on Basic Neuroscience Research</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com.proxy.library.emory.edu/journal/10.1002/(ISSN)1531-8249/policy_on_authorship.htm" title="Policy on Authorship" shape="rect">Policy on Authorship</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com.proxy.library.emory.edu/journal/10.1002/(ISSN)1531-8249/plagiarism_and_redundancy.htm" title="Plagiarism and Redundancy" shape="rect">Plagiarism and Redundancy</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://ordering.onlinelibrary.wiley.com.proxy.library.emory.edu/members/Membership.asp?ref=1531-8249" title="Membership Information" shape="rect">Membership Information</a></li></ul>     </div>             <script language="JavaScript" src="http://ad.uk.doubleclick.net/adj/wly.neurology_000086/annls-neuro_ANA;tile=2;sz=160x600,160x320,160x160,120x600;doi=10.1002/ana.21610;ord=535599965?" type="text/javascript" xml:space="preserve"></script> <noscript><a href="http://ad.uk.doubleclick.net/jump/wly.neurology_000086/annls-neuro_ANA;tile=2;sz=160x600,160x320,160x160,120x600;doi=10.1002/ana.21610;ord=535599965?" target="_blank" shape="rect">
        <img src="http://ad.uk.doubleclick.net/ad/wly.neurology_000086/annls-neuro_ANA;tile=2;sz=160x600,160x320,160x160,120x600;doi=10.1002/ana.21610;ord=535599965?" border="0" alt="" />
    </a></noscript>  </div>  <div id="content">     <div xmlns="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com.proxy.library.emory.edu/namespaces/ol/xsl-lib" id="banner" style="background-image: url('http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/(ISSN)1531-8249/asset/olbannerwallpaper.gif?v=1&amp;s=6348b2ba8d8a63b911c84ea2d055a277b0dc2226')"><img class="left" src="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/(ISSN)1531-8249/asset/olbannerleft.gif?v=1&amp;s=d36d5ebb3caa1b29d7f078a97c52973b0963daf2" alt="" /><img class="right" src="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/(ISSN)1531-8249/asset/olbannerright.gif?v=1&amp;s=078041b213f6959d63575a593f880457c45116f0" alt="" /></div>      <div id="mainContent">                                                                                                 <div xmlns="http://www.w3.org/1999/xhtml" class="citation articleInformationHeader" id="titleMeta"><div id="articleDesc"><p class="articleCategory">Original Article</p><div id="articleTitle"><span class="freeAccess" title="You have free access to this content">You have free access to this content</span><h1 class="articleTitle">Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects<a href="#fn1" rel="references:#fn1" shape="rect"><sup>&dagger;</sup></a></h1></div><div id="articleMeta"><ol id="authors"><li id="au1">Leslie M. Shaw PhD<sup>1,*</sup>, </li><li id="au2">Hugo Vanderstichele PhD<sup>2</sup>, </li><li id="au3">Malgorzata Knapik-Czajka PhD<sup>1</sup>, </li><li id="au4">Christopher M. Clark MD<sup>3</sup>, </li><li id="au5">Paul S. Aisen MD<sup>4</sup>, </li><li id="au6">Ronald C. Petersen MD<sup>5</sup>, </li><li id="au7">Kaj Blennow MD, PhD<sup>6</sup>, </li><li id="au8">Holly Soares PhD<sup>7</sup>, </li><li id="au9">Adam Simon PhD<sup>8</sup>, </li><li id="au10">Piotr Lewczuk MD, PhD<sup>9</sup>, </li><li id="au11">Robert Dean MD<sup>10</sup>, </li><li id="au12">Eric Siemers MD<sup>10</sup>, </li><li id="au13">William Potter MD<sup>8</sup>, </li><li id="au14">Virginia M.-Y. Lee PhD<sup>1</sup>, </li><li id="au15">John Q. Trojanowski MD, PhD<sup>1</sup></li></ol><p id="publishedOnlineDate">Article first published online: 18 MAR 2009</p><p id="doi">DOI:&nbsp;10.1002/ana.21610</p><p id="copyright" class="copyright">Copyright &copy; 2009 American Neurological Association</p></div><div id="articleParent"><p class="articleCategory">                 Issue               </p><div id="cover" class="journal"><div class="imgShadow"><img src="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/(ISSN)1531-8249/asset/cover.gif?v=1&amp;s=685ec69724c5ed4c8847ce939e70ceb45065856f" alt="Annals of Neurology" title="Annals of Neurology" /></div></div><div id="metaData"><h2 id="productTitle">Annals of Neurology</h2><div id="issueDetails"><p class="articleDetails"><a href="/doi/10.1002/ana.v65:4/issuetoc" shape="rect"><span id="volumeNumber">Volume 65</span>,  <span id="issueNumber">Issue 4</span>, </a> <span id="issuePages">pages 403&ndash;413</span>, <span id="issueDate">April 2009</span></p></div></div></div></div><div id="additionalInformation"><p class="articleCategory">Additional Information</p><div style="clear: left;"><div id="howToCite"><h4>How to Cite</h4><p id="citation">Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V. M.-Y. and Trojanowski, J. Q. (2009), Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology, 65:&nbsp;403&ndash;413. doi:&nbsp;10.1002/ana.21610</p></div><div id="authorsDetail"><h4>Author Information</h4><ol id="authorsAffiliations"><li class="affiliation"><sup>1</sup><p>Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA</p></li><li class="affiliation"><sup>2</sup><p>Department of Diagnostic Development, Innogenetics NV, Gent, Belgium</p></li><li class="affiliation"><sup>3</sup><p>Department of Neurology, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA</p></li><li class="affiliation"><sup>4</sup><p>University of California San Diego, San Diego, CA</p></li><li class="affiliation"><sup>5</sup><p>Mayo Clinic College of Medicine, Rochester, MN</p></li><li class="affiliation"><sup>6</sup><p>Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at G&ouml;teborg University, M&ouml;lndal, Sweden</p></li><li class="affiliation"><sup>7</sup><p>Pfizer Global Research and Development, Groton, CT</p></li><li class="affiliation"><sup>8</sup><p>Merck Research Laboratories, West Point, PA</p></li><li class="affiliation"><sup>9</sup><p>Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany</p></li><li class="affiliation"><sup>10</sup><p>Eli Lilly &amp; Company, Indianapolis, IN</p></li></ol><p id="contactDetails"><span class="email-label">Email: </span><span class="email">Leslie M. Shaw PhD (shawlmj@mail.med.upenn.edu) </span></p><p id="correspondence">*Correspondence: Leslie M. Shaw PhD, Department of Pathology and Laboratory Medicine, 7 Founders, University of Pennsylvania Medical Center, 3400 Spruce Street, Philadelphia, PA 19104</p><ol id="footnotes" class="noteGroup custom"><li id="fn1"><span class="bullet"><sup>&dagger;</sup></span><div class="para"><p>Potential conflict of interest: Nothing to report.</p></div></li></ol></div><div id="publicationHistoryDetails"><h4>Publication History</h4><ol><li>Issue published online: 27 APR 2009</li><li>Article first published online: 18 MAR 2009</li><li>Manuscript Accepted: 14 NOV 2008</li><li>Manuscript Revised: 4 NOV 2008</li><li>Manuscript Received: 18 SEP 2008</li></ol></div><div id="fundingInfo" class="fundingInfo"><h4>Funded by</h4><ul><li>NIH (National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering). Grant Numbers: AG024904, AG10124</li><li>Foundation for the National Institutes of Health</li><li>Pfizer</li><li>Wyeth Research</li><li>Bristol-Myers Squibb</li><li>Eli Lilly &amp; Company</li><li>GlaxoSmithKline</li><li>Merck &amp; Company</li><li>AstraZeneca AB</li><li>Novartis Pharmaceuticals Corporation</li><li>Alzheimer's Association</li><li>Eisai Global Clinical Development</li><li>Elan Corporation plc</li><li>Forest Laboratories</li><li>Institute for the Study of Aging</li><li>U.S. Food and Drug Administration</li><li>William Maul Measy-Truman G. Schnabel Jr MD Professorship of Geriatric Medicine and Gerontology</li></ul></div></div></div></div>                            </div> <div id="promosAndTools">                      <form method="post" action="/advanced/search/results" id="searchSite" class="searchForm" name="advancedSearchForm" enctype="application/x-www-form-urlencoded"><fieldset>                 <h2>SEARCH</h2>                 <div class="searchCriteria">                     <label for="scope">Search Scope</label>                     <select id="scope" name="scope"><option value="allContent">All content</option><option value="publicationTitles">Publication titles</option><option value="journal">In this journal</option><option value="issue" selected="selected">In this issue</option></select>                     <div>                         <label for="searchText">Search String</label>                         <input type="text" id="searchText" name="query" />                         <input name="searchSubmit2" id="searchSiteSubmit" type="image" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/images/searchSubmit.png" value="Go" alt="Search" />                     </div>                         <input type="hidden" value="10.1002/(ISSN)1531-8249" name="publicationDoi" />                         <input type="hidden" value="10.1002/ana.v65:4" name="issueDoi" />                     <input type="hidden" value="1" name="start" />                     <input type="hidden" value="20" name="resultsPerPage" />                 </div>             </fieldset><ul class="extraSearchOptions"><li><a href="/advanced/search" shape="rect">Advanced &gt;</a></li><li><a href="/myprofile/displaySavedSearches" shape="rect">Saved Searches &gt;</a></li></ul></form>          <form method="post" action="/search/citation/results" id="searchByCitation" class="searchForm" name="citationSearchForm" enctype="application/x-www-form-urlencoded"><fieldset>                 <h2>SEARCH BY CITATION</h2>                  <div class="searchCriteria">                   <div class="volume">                     <label for="volume">Volume:</label>     <input type="text" id="volume" name="volume" value="" class="searchVolume" />                     </div>                    <div class="issue">                      <label for="issue">Issue:</label>     <input type="text" id="issue" name="issue" value="" class="searchIssue" />                     </div>                    <div class="page">                      <label for="page">Page:</label>     <input type="text" id="page" name="page" value="" class="searchPage" />                     </div>                    <input name="citationSearchSubmit" id="citationSearchSubmit" type="image" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/images/searchSubmit.gif" value="Go" alt="Search" />                  </div>     <input type="hidden" id="publicationDoi" name="publicationDoi" value="10.1002/(ISSN)1531-8249" />           </fieldset></form>                 <div xmlns:w="http://www.wiley.com.proxy.library.emory.edu/namespaces/wiley" class="menuGroup"><h2>ARTICLE TOOLS</h2><ul class="titleTools"><li class="pdf"><a href="/doi/10.1002/ana.21610/pdf" title="Article in pdf format" id="journalToolsPdfLink" shape="rect">Get PDF (762K)</a></li><li class="save"><a href="/saveContent?doi=10.1002%252Fana.21610&amp;originUrl=%2Fdoi%2F10.1002%2Fana.21610%2Ffull" title="Save to My Profile" shape="rect">Save to My Profile</a></li><li class="email"><a href="/emailArticleLink?doi=10.1002/ana.21610" shape="rect">E-mail Link to this Article</a></li><li class="citation"><a href="/documentcitationdownload?publicationDoi=10.1002/(ISSN)1531-8249&amp;doi=10.1002/ana.21610&amp;type=journal" shape="rect">Export Citation for this Article</a></li><li class="requestPermissions"><a href="JavaScript:RightslinkPopUp('https://s100.copyright.com/AppDispatchServlet?publisherName=Wiley&amp;publication=ANA&amp;title=Cerebrospinal fluid biomarker signature in Alzheimer\'s disease neuroimaging initiative subjects&amp;publicationDate=01 APR 2009&amp;author=Leslie M. Shaw,Hugo Vanderstichele,Malgorzata Knapik&#x2010;Czajka,Christopher M. Clark,Paul S. Aisen,Ronald C. Petersen,Kaj Blennow,Holly Soares,Adam Simon,Piotr Lewczuk,Robert Dean,Eric Siemers,William Potter,Virginia M.&#x2010;Y. Lee,John Q. Trojanowski&amp;startPage=403&amp;endPage=413&amp;copyright=&amp;contentID=10.1002/ana.21610&amp;orderBeanReset=True')" shape="rect">Request Permissions</a></li></ul></div>  </div>      <div id="productContent">                       <div xmlns="http://www.w3.org/1999/xhtml" class="tabbedContent"><ul><li><a href="abstract" title="Link to article abstract" shape="rect">Abstract</a></li><li class="active"><span>Article</span></li><li><a href="references" title="Link to article references" shape="rect">References</a></li><li><a href="citedby" title="Other articles that have cited this article" shape="rect">Cited By</a></li></ul></div>           <div class="viewFullArticleAndPdf">             <div class="viewFullArticleAndPdfOptions">                                <a href="/doi/10.1002/ana.21610/pdf" title="Article in pdf format" id="topPdfLink" shape="rect">Get PDF (762K)</a>                             </div>         </div>                 <div xmlns="http://www.w3.org/1999/xhtml" id="fulltext"><div id="abstract"><div class="headingCont"><h3>Abstract</h3></div><ol class="jumpList"><li><a href="#leftBorder" shape="rect">Top of page</a></li><li><a href="#abstract" shape="rect">Abstract</a></li><li><a href="#sec1-1" shape="rect">Subjects and Methods</a></li><li><a href="#sec1-2" shape="rect">Results</a></li><li><a href="#sec1-3" shape="rect">Discussion</a></li><li><a href="#sec1-ack-1" shape="rect">Acknowledgements</a></li><li><a href="#app1" shape="rect">Appendix</a></li><li><a href="#wol-references" shape="rect">References</a></li></ol><div class="section" id="abs1-1"><h4>Objective</h4><div class="para"><p>Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects.</p></div></div><div class="section" id="abs1-2"><h4>Methods</h4><div class="para"><p>Amyloid-&beta; 1 to 42 peptide (A&beta;<sub>1&ndash;42</sub>), total tau (t-tau), and tau phosphorylated at the threonine 181 were measured in (1) cerebrospinal fluid (CSF) samples obtained during baseline evaluation of 100 mild AD, 196 mild cognitive impairment, and 114 elderly cognitively normal (NC) subjects in ADNI; and (2) independent 56 autopsy-confirmed AD cases and 52 age-matched elderly NCs using a multiplex immunoassay. Detection of an AD CSF profile for t-tau and A&beta;<sub>1&ndash;42</sub> in ADNI subjects was achieved using receiver operating characteristic cut points and logistic regression models derived from the autopsy-confirmed CSF data.</p></div></div><div class="section" id="abs1-3"><h4>Results</h4><div class="para"><p>CSF A&beta;<sub>1&ndash;42</sub> was the most sensitive biomarker for AD in the autopsy cohort of CSF samples: receiver operating characteristic area under the curve of 0.913 and sensitivity for AD detection of 96.4%. In the ADNI cohort, a logistic regression model for A&beta;<sub>1&ndash;42</sub>, t-tau, and <em>APO</em>&epsilon;<em>4</em> allele count provided the best assessment delineation of mild AD. An AD-like baseline CSF profile for t-tau/A&beta;<sub>1&ndash;42</sub> was detected in 33 of 37 ADNI mild cognitive impairment subjects who converted to probable AD during the first year of the study.</p></div></div><div class="section" id="abs1-4"><h4>Interpretation</h4><div class="para"><p>The CSF biomarker signature of AD defined by A&beta;<sub>1&ndash;42</sub> and t-tau in the autopsy-confirmed AD cohort and confirmed in the cohort followed in ADNI for 12 months detects mild AD in a large, multisite, prospective clinical investigation, and this signature appears to predict conversion from mild cognitive impairment to AD. Ann Neurol 2009</p></div></div></div><div class="section" id="sec1-bdy-1"><div class="para"><p>If the clinical diagnosis of probable AD is imprecise with accuracy rates of approximately 90% or lower using established consensus criteria for probable AD, but definite AD requires autopsy confirmation, it is not surprising that diagnostic accuracy is lower at early and presymptomatic stages of AD.<a href="#bib1" rel="references:#bib1 #bib2 #bib3 #bib4" class="referenceLink" title="Link to bibliographic citations" shape="rect">1&ndash;4</a> It is believed that the development of full-blown AD takes place over an approximately 20-year prodromal period, but this is difficult to determine in the absence of biomarkers that reliably signal the onset of nascent disease before the emergence of measurable cognitive impairments. Because intervention with disease-modifying therapies for AD is likely to be most efficacious before significant neurodegeneration has occurred, there is an urgent need for biomarker-based tests that enable a more accurate and early diagnosis of AD.<a href="#bib5" rel="references:#bib5 #bib6 #bib7" class="referenceLink" title="Link to bibliographic citations" shape="rect">5&ndash;7</a> Moreover, such tests could also improve monitoring AD progression, evaluation of new AD therapies, and enrichment of AD cohorts with specific subsets of AD subjects in clinical trials.</p></div><div class="para"><p>The defining lesions of AD are neurofibrillary tangles and senile plaques formed, respectively, by neuronal accumulations of abnormal hyperphosphorylated tau filaments and extracellular deposits of amyloid &beta; (A&beta;) fibrils, mostly the 1 to 42 peptide (A&beta;<sub>1-42</sub>), the least soluble of the known A&beta; peptides produced from A&beta; precursor protein by the action of various peptidases.<a href="#bib1" rel="references:#bib1 #bib2 #bib3" class="referenceLink" title="Link to bibliographic citations" shape="rect">1&ndash;3</a> Hence, for these and other reasons summarized in consensus reports on AD biomarkers, cerebrospinal fluid (CSF), total tau (t-tau), and A&beta; were identified as being among the most promising and informative AD biomarkers.<a href="#bib5" rel="references:#bib5" class="referenceLink" title="Link to bibliographic citation" shape="rect">5</a>, <a href="#bib6" rel="references:#bib6" class="referenceLink" title="Link to bibliographic citation" shape="rect">6</a> Increased levels of tau in CSF are thought to occur after its release from damaged and dying neurons that harbor dystrophic tau neurites and tangles, whereas reduced CSF levels of A&beta;<sub>1&ndash;42</sub> are believed to result from large-scale accumulation of this least soluble of A&beta; peptides into insoluble plaques in the AD brain. The combination of increased CSF concentrations of t-tau and phosphotau (p-tau) species and decreased concentrations of A&beta;<sub>1&ndash;42</sub> are considered to be a pathological CSF biomarker signature that is diagnostic for AD.<a href="#bib5" rel="references:#bib5" class="referenceLink" title="Link to bibliographic citation" shape="rect">5</a>, <a href="#bib6" rel="references:#bib6" class="referenceLink" title="Link to bibliographic citation" shape="rect">6</a>, <a href="#bib8" rel="references:#bib8" class="referenceLink" title="Link to bibliographic citation" shape="rect">8</a>, <a href="#bib9" rel="references:#bib9" class="referenceLink" title="Link to bibliographic citation" shape="rect">9</a> Notably, recent studies have provided compelling preliminary data to suggest that this combination of CSF tau and A&beta; biomarker changes may predict the conversion to AD in mild cognitive impairment (MCI) subjects.<a href="#bib10" rel="references:#bib10" class="referenceLink" title="Link to bibliographic citation" shape="rect">10</a> Thus, an increase in levels of CSF tau associated with a decline in levels of CSF A&beta;<sub>1&ndash;42</sub> may herald the onset of AD before it becomes clinically manifest.</p></div><div class="para"><p>However, before the utility of CSF A&beta;<sub>1&ndash;42</sub> and tau concentrations for diagnosis of AD can be established, it is critical to standardize the methodology for their measurement.<a href="#bib5" rel="references:#bib5 #bib6 #bib7 #bib8" class="referenceLink" title="Link to bibliographic citations" shape="rect">5&ndash;8</a>, <a href="#bib10" rel="references:#bib10" class="referenceLink" title="Link to bibliographic citation" shape="rect">10</a> For example, among the published studies of CSF tau and A&beta;, there is considerable variability in the observed levels of these analytes, as well as their diagnostic sensitivity and specificity. This is attributable to variability in analytical methodology standardization and other factors that differ between studies of the same CSF analytes in similar but not identical cohorts.<a href="#bib5" rel="references:#bib5 #bib6 #bib7" class="referenceLink" title="Link to bibliographic citations" shape="rect">5&ndash;7</a></p></div><div class="para"><p>The Alzheimer's Disease Neuroimaging Initiative (ADNI) was launched in 2004 to address these and other limitations in AD biomarkers (see reviews in Shaw and colleagues<a href="#bib7" rel="references:#bib7" class="referenceLink" title="Link to bibliographic citation" shape="rect">7</a> and Mueller and coauthors,<a href="#bib11" rel="references:#bib11" class="referenceLink" title="Link to bibliographic citation" shape="rect">11</a> and the ADNI Web site [<!--TODO: clickthrough URL--><a href="http://www.adni-info.org/index" title="Link to external resource: http://www.adni-info.org/index" shape="rect">http://www.adni-info.org/index</a>] where the ADNI grant and all ADNI data are posted for public access). To this end, the Biomarker Core of ADNI conducts studies on ADNI-derived CSF samples to measure CSF A&beta;<sub>1&ndash;42</sub>, t-tau, and p-tau (tau phosphorylated at threonine181 [p-tau<sub>181p</sub>]) in standardized assays. Evaluation of CSF obtained at baseline evaluation of 416 of the 819 ADNI subjects is now complete, and we report here our findings on the performance of these tests using a standardized multiplex immunoassay system that measures the biomarkers simultaneously in the same sample aliquot in ADNI subjects and in an independent cohort of autopsy-confirmed AD cases.</p></div></div><div class="section" id="sec1-1"><div class="headingCont"><h3>Subjects and Methods</h3></div><ol class="jumpList"><li><a href="#leftBorder" shape="rect">Top of page</a></li><li><a href="#abstract" shape="rect">Abstract</a></li><li><a href="#sec1-1" shape="rect">Subjects and Methods</a></li><li><a href="#sec1-2" shape="rect">Results</a></li><li><a href="#sec1-3" shape="rect">Discussion</a></li><li><a href="#sec1-ack-1" shape="rect">Acknowledgements</a></li><li><a href="#app1" shape="rect">Appendix</a></li><li><a href="#wol-references" shape="rect">References</a></li></ol><div class="para"><p>The ADNI is a large, multicenter, longitudinal neuroimaging study, launched in 2004 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies, and nonprofit organizations. ADNI includes 819 adult subjects, 55 to 90 years old, who meet entry criteria for a clinical diagnosis of amnestic MCI (n = 397), probable AD (n = 193), or normal cognition (n = 229). Participants receive baseline and periodic physical and neurological examinations and standardized neuropsychological assessments, and provide biological samples (blood, urine, and in a subset, CSF) throughout the study. Imaging (magnetic resonance imaging and for a subset, F-fluorodeoxyglucose positron emission tomography and Pittsburgh compound B positron emission tomography) is performed at baseline and at regular intervals thereafter (for reviews and more details, see Shaw and colleagues,<a href="#bib7" rel="references:#bib7" class="referenceLink" title="Link to bibliographic citation" shape="rect">7</a> Mueller and coauthors,<a href="#bib11" rel="references:#bib11" class="referenceLink" title="Link to bibliographic citation" shape="rect">11</a> and <!--TODO: clickthrough URL--><a href="http://www.adni-info.org/" title="Link to external resource: http://www.adni-info.org/" shape="rect">http://www.adni-info.org/</a>). All AD subjects met National Institute of Neurological and Communication Disorders/Alzheimer's Disease and Related Disorders Association criteria for probable AD with a Mini-Mental State Examination score between 20 and 26, a global Clinical Dementia Rating of 0.5 or 1, a sum-of-boxes Clinical Dementia Rating of 1.0 to 9.0, and, therefore, are only mildly impaired. Entry criteria for amnestic MCI subjects include a Mini-Mental State Examination score of 24 to 30 and a Memory Box score of at least 0.5, whereas other details on the ADNI cohort can be found online at: <!--TODO: clickthrough URL--><a href="http://www.nia.nih.gov.proxy.library.emory.edu/Alzheimers/ResearchInformation/ClinicalTrials/ADNI.htm" title="Link to external resource: http://www.nia.nih.gov.proxy.library.emory.edu/Alzheimers/ResearchInformation/ClinicalTrials/ADNI.htm" shape="rect">http://www.nia.nih.gov.proxy.library.emory.edu/Alzheimers/ResearchInformation/ClinicalTrials/ADNI.htm</a>. In brief, exclusion criteria included any serious neurological disease other than possible AD, any history of brain lesions or head trauma, or psychoactive medication use (including antidepressants, neuroleptics, chronic anxiolytics, or sedative hypnotics).</p></div><div class="para"><p>Baseline CSF samples were obtained in the morning after an overnight fast from 416 ADNI subjects (AD = 102, MCI = 200, NC = 114 with average [&plusmn; standard deviation] ages of 75 &plusmn; 8, 75 &plusmn; 7, and 76 &plusmn; 5 years, respectively; Table <a href="#tbl1" rel="references:#tbl1" class="tableLink" title="Link to table" shape="rect">1</a>) from individuals enrolled at 56 participating centers at the time the subjects entered ADNI (ie, baseline). Their demographic, clinical, and <em>APO</em>&epsilon; genotyping results are comparable with that in the full ADNI patient population (<!--TODO: clickthrough URL--><a href="http://www.adni-info.org/index" title="Link to external resource: http://www.adni-info.org/index" shape="rect">http://www.adni-info.org/index</a>). Lumbar puncture was performed with a 20- or 24-gauge spinal needle as described in the ADNI procedures manual (<!--TODO: clickthrough URL--><a href="http://www.adni-info.org/" title="Link to external resource: http://www.adni-info.org/" shape="rect">http://www.adni-info.org/</a>). In brief, CSF was collected into collection tubes provided to each site, then transferred into polypropylene transfer tubes followed by freezing on dry ice within 1 hour after collection, and shipped overnight to the ADNI Biomarker Core laboratory at the University of Pennsylvania Medical Center on dry ice. Aliquots (0.5ml) were prepared from these samples after thawing (1 hour) at room temperature and gentle mixing. The aliquots were stored in bar code&ndash;labeled polypropylene vials at &minus;80&deg;C. Written informed consent was obtained for participation in these studies, as approved by the institutional review board at each participating center.</p></div><div class="table" id="tbl1"><table class="topbotR"><caption><span class="tTitle"><span class="label">Table&nbsp;1.&nbsp;</span>Demographic Characteristics of Alzheimer's Disease Neuroimaging Initiative Study Subjects Who Provided a Cerebrospinal Fluid Sample at the Baseline Visit</span></caption><tbody class="vTop"><tr class="norsep hCenter"><td rowspan="1" colspan="1"><img alt="inline image" src="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/ana.21610/asset/image_n/ntbl001.jpg?v=1&amp;t=ggdx471i&amp;s=295ccd21dfbbb91f4d66f92293609576562f0144" class="inlineGraphic" /></td></tr></tbody></table></div><div class="para"><p>An independent set of premortem CSF samples from 56 autopsy-confirmed AD cases and 52 cognitively normal elderly subjects followed by the University of Pennsylvania Alzheimer's Disease Clinical Core provided an independent analysis sample set that was matched with the ADNI samples with respect to age (mean &plusmn; standard deviation [95% confidence interval]: 71 &plusmn; 10 [69&ndash;74] and 70 &plusmn; 11 [67&ndash;73] years, respectively) at the time of their lumbar puncture. The cases and control subjects were evaluated and followed as described previously,<a href="#bib12" rel="references:#bib12 #bib13 #bib14" class="referenceLink" title="Link to bibliographic citations" shape="rect">12&ndash;14</a> and all of these CSF samples were collected at University of Pennsylvania Alzheimer's Disease Clinical Core using standardized methodology including storage of aliquots in polypropylene vials maintained in the repository at &minus;80&deg;C.<a href="#bib12" rel="references:#bib12 #bib13 #bib14" class="referenceLink" title="Link to bibliographic citations" shape="rect">12&ndash;14</a> Written informed consent was obtained for participation in these studies, which was approved by the University of Pennsylvania Institutional Review Board.</p></div><div class="para"><p>A&beta;<sub>1&ndash;42</sub>, t-tau, and p-tau<sub>181p</sub> were measured in each of the 416 CSF ADNI baseline aliquots using the multiplex xMAP Luminex platform (Luminex Corp, Austin, TX) with Innogenetics (INNO-BIA AlzBio3; Ghent, Belgium; for research use&ndash;only reagents) immunoassay kit&ndash;based reagents. Full details of this combination of immunoassay reagents and analytical platform are provided elsewhere.<a href="#bib15" rel="references:#bib15" class="referenceLink" title="Link to bibliographic citation" shape="rect">15</a>, <a href="#bib16" rel="references:#bib16" class="referenceLink" title="Link to bibliographic citation" shape="rect">16</a> In brief, Innogenetics kit reagents included well-characterized capture monoclonal antibodies specific for A&beta;<sub>1&ndash;42</sub>(4D7A3), t-tau(AT120), and p-tau<sub>181p</sub>(AT270), each chemically bonded to unique sets of color-coded beads, and analyte-specific detector antibodies (HT7, 3D6). Calibration curves were produced for each biomarker using aqueous buffered solutions that contained the combination of three biomarkers at concentrations ranging from 56 to 1,948pg/ml for recombinant tau, 27 to 1,574pg/ml for synthetic A&beta;<sub>1&ndash;42</sub> peptide, and 8 to 230pg/ml for a tau synthetic peptide phosphorylated at the threonine 181 position (ie, the p-tau<sub>181p</sub> standard). Before performing these analyses of the ADNI and the independent autopsy-based CSF samples in the ADNI University of Pennsylvania ADNI Biomarker Core laboratory, an interlaboratory study was conducted to qualify the performance conditions, including all major variables that can affect the test results, for the immunoassay reagents and analytical platform. These studies were conducted using strategies and procedures to standardize the assay similar to those that Vanderstichele and colleagues<a href="#bib16" rel="references:#bib16" class="referenceLink" title="Link to bibliographic citation" shape="rect">16</a> described. This investigation (Shaw and colleagues, manuscript in preparation, but see summary of these data online at: <!--TODO: clickthrough URL--><a href="http://www.adni-info.org/" title="Link to external resource: http://www.adni-info.org/" shape="rect">http://www.adni-info.org/</a>) provided the basis for achieving day-to-day reproducibility for the three biomarkers of less than 10% variation for CSF pool samples and less than 7% for aqueous quality controls. The ADNI baseline CSF samples were analyzed over a 14-day period and included test&ndash;retest analyses of 29 of the samples that further substantiated the analytical performance (<em>r</em><sup>2</sup> values for comparison of initial test result with retest result of 0.98, 0.90, and 0.85 for t-tau, A&beta;<sub>1&ndash;42</sub>, and p-tau<sub>181p</sub>, respectively for 29 randomly selected samples). Only subjects with a valid test result for all 3 biomarkers are included in this study, that is, 114 NC, 196 MCI, and 100 AD subjects.</p></div><div class="para"><p><em>APO</em>&epsilon; genotyping was done for all ADNI study candidates using EDTA blood samples collected at the screening visit (see Table <a href="#tbl1" rel="references:#tbl1" class="tableLink" title="Link to table" shape="rect">1</a>). TaqMan quantitative polymerase chain reaction assays were used for genotyping <em>APO</em>&epsilon; nucleotides 334 T/C and 472 CT with an ABI 7900 real-time thermocycler (Applied Biosystems, Foster City, CA) using DNA freshly prepared from EDTA whole blood. A total of 96 samples randomly selected from the total of 1,131 subjects screened before inclusion (or exclusion) into the ADNI study were retested by sequencing using an ABI 3130 sequencer (Applied Biosystems). Except for the 5 samples that failed to sequence, the remaining 91 were concordant with the TaqMan genotyping results.</p></div><div class="para"><p>Receiver operating characteristic curve (ROC) and logistic regression (LR) analyses were done using SAS v 9.1.3 (SAS Institute, Cary, NC) and R v 2.7.1. Between-group differences for each biomarker were assessed by the Mann&ndash;Whitney <em>U</em> test using GraphPad Prism, v 5.</p></div></div><div class="section" id="sec1-2"><div class="headingCont"><h3>Results</h3></div><ol class="jumpList"><li><a href="#leftBorder" shape="rect">Top of page</a></li><li><a href="#abstract" shape="rect">Abstract</a></li><li><a href="#sec1-1" shape="rect">Subjects and Methods</a></li><li><a href="#sec1-2" shape="rect">Results</a></li><li><a href="#sec1-3" shape="rect">Discussion</a></li><li><a href="#sec1-ack-1" shape="rect">Acknowledgements</a></li><li><a href="#app1" shape="rect">Appendix</a></li><li><a href="#wol-references" shape="rect">References</a></li></ol><div class="para"><p>Mean &plusmn; standard deviation values for CSF t-tau, A&beta;<sub>1&ndash;42</sub>, p-tau<sub>181p</sub>, t-tau/A&beta;<sub>1&ndash;42</sub> and p-tau<sub>181p</sub>/A&beta;<sub>1&ndash;42</sub>, for the ADNI AD, MCI, and NC study groups are summarized in Table <a href="#tbl2" rel="references:#tbl2" class="tableLink" title="Link to table" shape="rect">2</a>. These data confirm the findings of the majority of single and smaller multicenter studies for these biomarkers in AD subjects wherein most investigators report increases in t-tau, p-tau<sub>181p</sub> concentrations, t-tau/A&beta;<sub>1&ndash;42</sub>, and p-tau<sub>181p</sub>/A&beta;<sub>1&ndash;42</sub> ratio values when comparing NC with MCI, and then further increases in these values when comparing MCI with AD.<a href="#bib7" rel="references:#bib7 #bib8 #bib9 #bib10" class="referenceLink" title="Link to bibliographic citations" shape="rect">7&ndash;10</a>, <a href="#bib12" rel="references:#bib12 #bib13 #bib14 #bib15 #bib16" class="referenceLink" title="Link to bibliographic citations" shape="rect">12&ndash;16</a> A&beta;<sub>1&ndash;42</sub> average concentrations, on the other hand, decrease when comparing NC with MCI, then decrease further in comparing MCI with AD.<a href="#bib7" rel="references:#bib7 #bib8 #bib9 #bib10" class="referenceLink" title="Link to bibliographic citations" shape="rect">7&ndash;10</a>, <a href="#bib12" rel="references:#bib12 #bib13 #bib14 #bib15 #bib16" class="referenceLink" title="Link to bibliographic citations" shape="rect">12&ndash;16</a> Closer examination of the distribution of each biomarker and ratios demonstrated that the distributions are not normal, and for A&beta;<sub>1&ndash;42</sub>, the distributions appear to be bimodal (Fig <a href="#fig1" rel="references:#fig1" class="figureLink" title="Link to figure" shape="rect">1</a>). Typical published single enzyme-linked immunosorbent assay test values for tau and A&beta;<sub>1&ndash;42</sub> are generally up to two to four times greater than with the multiplex xMAP Lumnex platform using the INNO-BIA AlzBio3 immunoassay reagents, although the two methods correlate well with each other and provide equivalent diagnostic performance when CSF samples are analyzed by both methods within the same study.<a href="#bib15" rel="references:#bib15 #bib16 #bib17" class="referenceLink" title="Link to bibliographic citations" shape="rect">15&ndash;17</a> In the ADNI Biomarker Core, we observed single-test enzyme-linked immunosorbent assay t-tau concentrations approximately 4-fold greater, A&beta;<sub>1&ndash;42</sub> approximately 2-fold greater, and p-tau<sub>181p</sub> approximately 25% greater than xMAP (data not shown). The differences in the absolute values between the two assay formats could be related to differences in the monoclonal antibodies used, assay test conditions (time, temperature, multiplexing), and/or the fact that the calibrators are not produced in the same matrix (CSF).</p></div><div class="table" id="tbl2"><table class="topbotR"><caption><span class="tTitle"><span class="label">Table&nbsp;2.&nbsp;</span>Cerebrospinal Fluid Biomarker Concentrations and Ratios in Alzheimer's Disease Neuroimaging Initiative Study Subjects at Baseline</span></caption><tbody class="vTop"><tr class="norsep hCenter"><td rowspan="1" colspan="1"><img alt="inline image" src="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/ana.21610/asset/image_n/ntbl002.jpg?v=1&amp;t=ggdx4722&amp;s=0ef17dc7e5fa0c2e6f64dd6b30abeabbb8fe9a8c" class="inlineGraphic" /></td></tr></tbody></table></div><div class="figure hh" id="fig1"><div class="caption" id="fig1_caption"><p><span class="label">Figure&nbsp;1. </span>(A) Frequency distribution of cerebrospinal fluid (CSF) amyloid-&beta; 1 to 42 peptide (A&beta;<sub>1&ndash;42</sub>) concentration in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Alzheimer's disease (AD), mild cognitive impairment (MCI), and cognitively normal (NC) groups at their baseline visit. <em>Dotted vertical lines</em> within each diagnosis is the A&beta;<sub>1&ndash;42</sub> cutoff concentration of 192pg/ml determined from the ADNI-independent autopsy-based AD CSF samples. (B) A&beta;<sub>1&ndash;42</sub> concentrations in CSF, collected at the baseline visit, of 37 ADNI MCI subjects who at their 1-year visit converted to a diagnosis of probable AD. Data points for the MCI&rarr;AD converters are presented as a <em>horizontal dot plot</em> with the <em>x</em>-axis scale identical to that of the A&beta;<sub>1&ndash;42</sub> frequency plot for the entire ADNI MCI group.</p></div><a class="figZoom" title="Link to full-size figure" href="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/ana.21610/asset/image_n/nfig001.jpg?v=1&amp;t=ggdx4725&amp;s=d068b741c48bd01e97aac83de83dc37115125f0f" shape="rect"><img id="fig1_img" alt="thumbnail image" src="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/ana.21610/asset/image_t/tfig001.gif?v=1&amp;t=ggdx4726&amp;s=ed1cdd41ec45b01b3ee53b8e7f88227682115412" /></a></div><div class="para"><p>Premortem CSF was obtained from separate, ADNI-independent groups of autopsy-confirmed AD cases and additional NC subjects who were matched for age to provide a pathological basis for these biomarker measurements. The CSF t-tau, p-tau<sub>181p</sub>, and A&beta;<sub>1&ndash;42</sub> concentrations of these individuals were measured using the same reagents and assay system described earlier for the baseline CSF samples from ADNI subjects. These data are summarized in Table <a href="#tbl3" rel="references:#tbl3" class="tableLink" title="Link to table" shape="rect">3</a>. The same trends for each of the mean concentrations or ratio values for the t-tau and A&beta; biomarker parameters were observed for these ADNI-independent subjects and autopsy-confirmed AD cases, as well as in the age-matched ADNI-independent NC group as observed for the ADNI AD and NC cohorts (see Table <a href="#tbl3" rel="references:#tbl3" class="tableLink" title="Link to table" shape="rect">3</a> and compare Figs <a href="#fig2" rel="references:#fig2" class="figureLink" title="Link to figure" shape="rect">2</a> and <a href="#fig3" rel="references:#fig3" class="figureLink" title="Link to figure" shape="rect">3</a>).</p></div><div class="table" id="tbl3"><table class="topbotR"><caption><span class="tTitle"><span class="label">Table&nbsp;3.&nbsp;</span>Cerebrospinal Fluid Biomarker Concentrations and Ratios in Non&ndash;Alzheimer's Disease Neuroimaging Initiative Samples Collected before Autopsy for Alzheimer's Disease and an Age-Matched Elderly Cognitively Normal Control Group</span></caption><tbody class="vTop"><tr class="norsep hCenter"><td rowspan="1" colspan="1"><img alt="inline image" src="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/ana.21610/asset/image_n/ntbl003.jpg?v=1&amp;t=ggdx472a&amp;s=f15d536fade3392d6bd6f657945af40d31663551" class="inlineGraphic" /></td></tr></tbody></table></div><div class="figure hh" id="fig2"><div class="caption" id="fig2_caption"><p><span class="label">Figure&nbsp;2. </span>Plot of cerebrospinal fluid (CSF) tau concentration versus CSF amyloid-&beta; 1 to 42 peptide (A&beta;<sub>1&ndash;42</sub>) concentration for the autopsy-confirmed Alzheimer's disease (AD) cases (<em>solid circles</em>) and elderly cognitively normal (NC) subjects (<em>open circles</em>).</p></div><a class="figZoom" title="Link to full-size figure" href="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/ana.21610/asset/image_n/nfig002.jpg?v=1&amp;t=ggdx472c&amp;s=fc548480a0b32bb0b73071b2a239536a3811d3dd" shape="rect"><img id="fig2_img" alt="thumbnail image" src="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/ana.21610/asset/image_t/tfig002.gif?v=1&amp;t=ggdx472d&amp;s=535a316ca3164fc6975572c01eb3afd07616a737" /></a></div><div class="figure hh" id="fig3"><div class="caption" id="fig3_caption"><p><span class="label">Figure&nbsp;3. </span>Plot of cerebrospinal fluid (CSF) tau concentration versus CSF amyloid-&beta; 1 to 42 peptide (A&beta;<sub>1&ndash;42</sub>) concentration for the Alzheimer's Disease Neuroimaging Initiative (ADNI) probable Alzheimer's disease (AD; <em>solid circles</em>), mild cognitive impairment (MCI; <em>squares</em>), and elderly cognitively normal (NC; <em>open circles</em>) subjects.</p></div><a class="figZoom" title="Link to full-size figure" href="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/ana.21610/asset/image_n/nfig003.jpg?v=1&amp;t=ggdx472f&amp;s=76c7d329250b41a643ce8c97dfa86d634b6288c3" shape="rect"><img id="fig3_img" alt="thumbnail image" src="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/ana.21610/asset/image_t/tfig003.gif?v=1&amp;t=ggdx472f&amp;s=67aa8d7604f36bea0843e235191973a87522e903" /></a></div><div class="para"><p>ROC analyses of the autopsy-confirmed AD cases versus the NC group provided cutpoint concentrations achieved at the greatest diagnostic test accuracy and assessments of the diagnostic sensitivity and specificity, and the positive and negative predictive values for the biomarker measurements as summarized in Table <a href="#tbl4" rel="references:#tbl4" class="tableLink" title="Link to table" shape="rect">4</a>. The greatest ROC area under the curve (AUC) value for a single parameter was obtained for A&beta;<sub>1&ndash;42</sub> (0.913). This biomarker had the greatest sensitivity value (96.4%) and negative predictive value of 95.2% (ie, the probability that AD is not present when the test is negative, ie, when CSF A&beta;<sub>1&ndash;42</sub> concentration is greater than the cutoff value of 192pg/ml and comparing AD with NC subjects), and diagnostic test accuracy (87.0%) (ie, the percentages of all results for the AD vs NC groups that are classified correctly) of the three single biomarkers or the two biomarker ratios (see Table <a href="#tbl4" rel="references:#tbl4" class="tableLink" title="Link to table" shape="rect">4</a>). The diagnostic specificity for A&beta;<sub>1&ndash;42</sub> was 76.9%. The diagnostic specificity for t-tau, on the other hand, was 92.3%, and the greater for all five test parameters was the positive predictive value of 90.7% (ie, the probability that the disease is present when the t-tau CSF concentration value is greater than the cutoff concentration value of 93pg/ml). The test accuracy and sensitivity were 80.6 and 69.6%, respectively, for t-tau. For the t-tau/A&beta;<sub>1&ndash;42</sub> ratio, the AUC value is 0.917, the sensitivity and specificity values are 85.7 and 84.6%, the test accuracy is 85.2%, positive predictive value is 85.7%, and negative predictive value is 84.6%.</p></div><div class="table" id="tbl4"><table class="topbotR"><caption><span class="tTitle"><span class="label">Table&nbsp;4.&nbsp;</span>Receiver Operating Characteristic Curve Parameters for Non&ndash;Alzheimer's Disease Neuroimaging Initiative Autopsy-Based Alzheimer's Disease Cases versus Cognitively Normal Subjects</span></caption><tbody class="vTop"><tr class="norsep hCenter"><td rowspan="1" colspan="1"><img alt="inline image" src="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/ana.21610/asset/image_n/ntbl004.jpg?v=1&amp;t=ggdx472l&amp;s=a7e4826f1c2312a3e4eaae28ab872fcbeb6471cd" class="inlineGraphic" /></td></tr></tbody></table></div><div class="para"><p>LR analyses were performed using the variables sex, years of education, age at the time of lumbar puncture, <em>APO</em>&epsilon;<em>4</em> allele expression (0, 1, or 2 <em>APO</em>&epsilon;<em>4</em> alleles), and each of the three biomarkers, with backward elimination and insertion into the model that had only A&beta;<sub>1&ndash;42</sub> and t-tau as variables to determine which variables contributed most to the discrimination between AD and NC. A&beta;<sub>1&ndash;42</sub>, t-tau, and <em>APO</em>&epsilon;<em>4</em> allele number were significant contributors to the LR model, whereas p-tau<sub>181p</sub> and the other variables were not. The LR model for A&beta;<sub>1&ndash;42</sub> + t-tau + <em>APO</em>&epsilon;<em>4</em>(1) + <em>APO</em>&epsilon;<em>4</em>(2) (LR<sub>TAA</sub>) is: Pi = 1/1 + exp(&minus;3.907 &minus; 0.0182*Tau + 0.0338*A&beta;<sub>1&ndash;42</sub> + {0 if no <em>APO</em>&epsilon;<em>4</em> allele is present; &minus;0.671 if 1 <em>APO</em>&epsilon;<em>4</em> allele is present; &minus;17.673 if 2 <em>APO</em>&epsilon;<em>4</em> alleles are present}). Using the LR<sub>TAA</sub> model as the independent variable and performing ROC analysis for the CSF biomarkers from the autopsy-confirmed AD cases in the cohort of ADNI-independent, age-matched AD and NC group, we found that the AUC, sensitivity, test accuracy, and negative predictive values improved modestly to 0.942, 98.2%, 89.9% and 97.2%, respectively (see Table <a href="#tbl4" rel="references:#tbl4" class="tableLink" title="Link to table" shape="rect">4</a>). Plots of CSF tau versus CSF A&beta;<sub>1&ndash;42</sub> concentrations are summarized in Figures <a href="#fig2" rel="references:#fig2" class="figureLink" title="Link to figure" shape="rect">2</a> and <a href="#fig3" rel="references:#fig3" class="figureLink" title="Link to figure" shape="rect">3</a>, respectively.</p></div><div class="para"><p>Because the <em>APO</em>&epsilon;<em>4</em> allele is the most robust genetic risk factor for sporadic AD, we performed comparisons of average values for each of the biomarkers and ratios thereof as summarized in Table <a href="#tbl5" rel="references:#tbl5" class="tableLink" title="Link to table" shape="rect">5</a> for the ADNI subjects who were carriers of zero, one, or two <em>APO</em>&epsilon;<em>4</em> alleles. Notably, as seen in Table <a href="#tbl5" rel="references:#tbl5" class="tableLink" title="Link to table" shape="rect">5</a>, A&beta;<sub>1&ndash;42</sub> concentration is lowest in AD, MCI, and NC subjects with two alleles of <em>APO</em>&epsilon;<em>4</em>, and concentrations increase as the number of alleles decreases. MCI subjects who had one or two <em>APO</em>&epsilon;<em>4</em> alleles had greater average t-tau and p-tau<sub>181p</sub> concentrations, as well as greater t-tau/A&beta;<sub>1&ndash;42</sub> and p-tau<sub>181p</sub>/A&beta;<sub>1&ndash;42</sub> ratio values than subjects lacking any <em>APO</em>&epsilon;<em>4</em> allele (<em>APO</em>&epsilon;<em>4</em>&minus;), although there was no difference between carriers of one versus two alleles. CSF t-tau concentrations in AD and NC subjects did not increase as a function of number of <em>APO</em>&epsilon;<em>4</em> alleles, and there was not a consistent dose&ndash;response effect for p-tau<sub>181p</sub> in either the AD or NC groups. Because there were only two of the elderly NC group who expressed two <em>APO</em>&epsilon;<em>4</em> alleles, it is not possible in this ADNI NC cohort to fully test for a relation between <em>APO</em>&epsilon;<em>4</em> allele number and CSF biomarker concentrations or ratios. Thus, because it is known that there is greater AD pathology in AD patients who are <em>APO</em>&epsilon;<em>4</em>+ (reviewed in Roses and Saunders's article<a href="#bib18" rel="references:#bib18" class="referenceLink" title="Link to bibliographic citation" shape="rect">18</a>), one might expect that ADNI NC and MCI subjects who are <em>APO</em>&epsilon;<em>4</em>+ would show more limited difference in their CSF t-tau and A&beta;<sub>1&ndash;42</sub> profile compared with the CSF profile of these AD biomarkers in their ADNI counterparts with early AD.</p></div><div class="table" id="tbl5"><table class="topbotR"><caption><span class="tTitle"><span class="label">Table&nbsp;5.&nbsp;</span>Mean Values for Biomarkers in Alzheimer's Disease Neuroimaging Initiative Patients, Stratified by Number of <em>APOE</em>&epsilon;<em>4</em> Alleles</span></caption><tbody class="vTop"><tr class="norsep hCenter"><td rowspan="1" colspan="1"><img alt="inline image" src="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/ana.21610/asset/image_n/ntbl005.jpg?v=1&amp;t=ggdx472v&amp;s=d62ff0636a5d8899904e3664005e8e5fac70e651" class="inlineGraphic" /></td></tr></tbody></table></div><div class="para"><p>As expected, there were ADNI MCI subjects who converted to a clinical diagnosis of probable AD during the first year of follow-up. As of August 15, 2008, there were a total of 37 MCI subjects who had provided CSF samples at baseline when they entered ADNI and who 12 months thereafter were documented to be converters to AD at the time of their year 1 visit (see CSF ADNI baseline biomarker data summarized in Table <a href="#tbl2" rel="references:#tbl2" class="tableLink" title="Link to table" shape="rect">2</a>). The average biomarker concentrations and ratio values for these MCI to AD converters were different (<em>p</em> &lt; 0.0001) from the corresponding results for the ADNI NC group, and as noted later, they had an AD-like CSF profile incidence comparable with that seen in the ADNI AD group (see Table <a href="#tbl2" rel="references:#tbl2" class="tableLink" title="Link to table" shape="rect">2</a> and Fig <a href="#fig1" rel="references:#fig1" class="figureLink" title="Link to figure" shape="rect">1</a>B). On the other hand, the three MCI subjects who back-converted to NC status showed an NC-like CSF tau and A&beta; profile at baseline. The CSF t-tau values for these MCI subjects were 69, 73, and 83pg/ml, all less than the cutoff value of 93pg/ml; the values for A&beta;<sub>1&ndash;42</sub> were 253, 233, and 285pg/ml, all greater than the cutoff value of 192pg/ml; and the values for p-tau<sub>181p</sub> were 21, 25, and 20pg/ml, two less than the cutoff value of 23pg/ml and one slightly more than it. The change in clinical diagnosis for these three MCI individuals was based on an improvement on several cognitive measures including the ADAS-Cog, Mini-Mental State Examination, and memory measures. These subjects also improved on the Clinical Dementia Rating according to informants. It should be noted that results for all three of these subjects were mild at the time of their initial diagnosis and consequently were just on the border of normal and MCI. Because of the small numbers of subjects, it is important to be cautious about drawing any definitive conclusions from these subjects, and it will be important to confirm this finding with greater numbers of MCI subjects at later stages in the study. Finally, application of the cut points for the three best pathologically based parameters, A&beta;<sub>1&ndash;42</sub>, t-tau/A&beta;<sub>1&ndash;42</sub>, and the LR<sub>TAA</sub> model, for the presence of an AD-like CSF profile in the ADNI AD, MCI, and NC groups, as well as in the MCI subjects who converted to AD, showed the following incidence of an AD-like CSF profile: 91, 88, and 89%, respectively, for AD; 74, 69, and 70%, respectively, for MCI; 38, 34, and 31%, respectively, for NC; and 86.5, 89, and 86.5%, respectively, for MCI converters to AD.</p></div></div><div class="section" id="sec1-3"><div class="headingCont"><h3>Discussion</h3></div><ol class="jumpList"><li><a href="#leftBorder" shape="rect">Top of page</a></li><li><a href="#abstract" shape="rect">Abstract</a></li><li><a href="#sec1-1" shape="rect">Subjects and Methods</a></li><li><a href="#sec1-2" shape="rect">Results</a></li><li><a href="#sec1-3" shape="rect">Discussion</a></li><li><a href="#sec1-ack-1" shape="rect">Acknowledgements</a></li><li><a href="#app1" shape="rect">Appendix</a></li><li><a href="#wol-references" shape="rect">References</a></li></ol><div class="para"><p>ADNI is a multisite, prospective clinical study funded by the National Institute on Aging, industry, and foundations (see Acknowledgements for details on sources for ADNI funding) with the following mission: (1) to develop standardized neuroimaging and biomarker methods for AD clinical trials; (2) to determine optimum methods for acquiring and processing brain images; (3) to validate AD neuroimaging and biomarker findings by correlating them with ADNI behavioral test data; and (4) to provide a database available to the public for all ADNI findings for further analysis.<a href="#bib7" rel="references:#bib7" class="referenceLink" title="Link to bibliographic citation" shape="rect">7</a>, <a href="#bib11" rel="references:#bib11" class="referenceLink" title="Link to bibliographic citation" shape="rect">11</a> This is the first report on studies of baseline CSF samples from ADNI subjects, and we measured tau and A&beta;<sub>1&ndash;42</sub> values in the approximately 50% of ADNI subjects who consented to lumbar puncture, including representatives of the AD, MCI, and NC groups. Our objective in this study was to establish a CSF profile for these biomarkers that might serve as CSF signatures for the presence of AD pathology, and thus aid in the identification of patients among elderly individuals with late-life cognitive impairment. To do this, we measured A&beta;<sub>1&ndash;42</sub>, t-tau, and p-tau<sub>181p</sub> in each of the 416 CSF ADNI baseline aliquots (102 = AD; 200 = MCI; 114 = NC) using the well-characterized and standardized multiplex xMAP Luminex platform with Innogenetics (INNO-BIA AlzBio3) immunoassay kit&ndash;based reagents.<a href="#bib15" rel="references:#bib15" class="referenceLink" title="Link to bibliographic citation" shape="rect">15</a>, <a href="#bib16" rel="references:#bib16" class="referenceLink" title="Link to bibliographic citation" shape="rect">16</a> We also performed these CSF measurements using the same methods on CSF samples from an ADNI-independent set of 56 autopsy-confirmed cases with AD and 52 age-matched NC subjects for comparison with the ADNI data set and to inform our interpretations of these ADNI data. Hence, this also is the first study to compare CSF data from ADNI subjects with those from a comparable ADNI-independent cohort of autopsy-confirmed AD cases. This enabled us to define an AD CSF profile for tau and A&beta; levels in the ADNI AD subjects and in the ADNI-independent autopsy-confirmed AD cases using ROC analyses and LR modeling (Fig <a href="#fig4" rel="references:#fig4" class="figureLink" title="Link to figure" shape="rect">4</a>). In brief, among the CSF biomarker studies here, CSF A&beta;<sub>1&ndash;42</sub> concentration was the most sensitive analyte for the detection of AD, thereby indicating that CSF A&beta;<sub>1&ndash;42</sub> is the most informative single AD biomarker both for the ADNI cohort and the ADNI-independent autopsy-confirmed cohort of AD cases. Specifically, for these CSF samples, we observed the following for CSF A&beta;<sub>1&ndash;42</sub>: ROC AUC = 0.913; sensitivity for detection of AD = 96.4%; negative predictive value = 95.2%; specificity for discriminating AD from elderly NC = 76.9%; and positive predictive value = 81.8% with an overall test accuracy of 87%.</p></div><div class="figure hh" id="fig4"><div class="caption" id="fig4_caption"><p><span class="label">Figure&nbsp;4. </span>(A) Receiver operating characteristic curve (ROC) curves for the non&ndash;Alzheimer's Disease Neuroimaging Initiative (ADNI) autopsy-based Alzheimer's disease (AD) cases versus non-ADNI cognitively normal (NC) subjects. The LR<sub>TAA</sub> model, amyloid-&beta; 1 to 42 peptide (A&beta;<sub>1&ndash;42</sub>), and tau/A&beta;<sub>1&ndash;42</sub> ratio are the independent variables whose ROC curves are shown. (B) ROC curves for ADNI probable AD versus NC subjects. CSF = cerebrospinal fluid.</p></div><a class="figZoom" title="Link to full-size figure" href="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/ana.21610/asset/image_n/nfig004.jpg?v=1&amp;t=ggdx473c&amp;s=4dbb1adf69f7e792a752396baa1cd43b0753dbe1" shape="rect"><img id="fig4_img" alt="thumbnail image" src="http://onlinelibrary.wiley.com.proxy.library.emory.edu/store/10.1002/ana.21610/asset/image_t/tfig004.gif?v=1&amp;t=ggdx473d&amp;s=278702cc71269f7d7f76fa570f1bc6b468b67450" /></a></div><div class="para"><p>Because these metrics are critical for the assessment of AD biomarkers,<a href="#bib7" rel="references:#bib7" class="referenceLink" title="Link to bibliographic citation" shape="rect">7</a> it is important to note that a sensitivity of 100% indicates that a diagnostic test identifies 100% of subjects with AD, whereas a test with 100% specificity distinguishes AD from non-AD subjects. Consensus reports recommend that informative biomarkers of AD should have a sensitivity and specificity of more than 85%.<a href="#bib5" rel="references:#bib5" class="referenceLink" title="Link to bibliographic citation" shape="rect">5</a>, <a href="#bib6" rel="references:#bib6" class="referenceLink" title="Link to bibliographic citation" shape="rect">6</a> On the other hand, prior probability is the frequency of a disease in specific populations, and the positive predictive value of an AD biomarker is the percentage of people who are positive for the biomarker and who also are confirmed to have definite AD at autopsy. Clinically useful biomarker tests should have a positive predictive value of more than 80%.<a href="#bib7" rel="references:#bib7" class="referenceLink" title="Link to bibliographic citation" shape="rect">7</a> The negative predictive value of a test also is informative because this indicates the percentage of people with a negative test who, at autopsy, prove not to have the disease. Thus, a negative predictive value of 100% indicates that the test completely rules out the possibility that an individual has the disease pathology when the test is performed. Clearly, a reliable AD biomarker with a high negative predictive value would be extremely useful. Given the values of these metrics for CSF A&beta;<sub>1&ndash;42</sub> reported here, our study identifies CSF A&beta;<sub>1&ndash;42</sub> as the most informative AD biomarker of those we examined in the context of the ADNI study. It is important to emphasize here that the diagnostic test outcomes described are applicable to the ADNI study subjects but not necessarily to individuals in other settings. For example, the prevalence of AD would be lower and the presence of other neurodegenerative disorders higher in memory disorder clinics or other clinical settings in which a patient is evaluated for a memory complaint. The performance of these tests in such patients would require further independent studies to derive the diagnostic utility of these biomarker tests.</p></div><div class="para"><p>However, it is likely that a panel of biomarkers rather than a single analyte will have the most utility for the diagnosis of AD, predicting which NC individuals and which subjects with MCI will progress to AD, as well as for monitoring the response of patients to disease-modifying therapies. Further studies are needed to confirm the potential utilities of the biomarkers examined here, but several studies indicate that CSF tau and A&beta; assays look increasingly promising for the early diagnosis of AD and recognizing those MCI subjects with the greatest likelihood to progress to AD.<a href="#bib10" rel="references:#bib10" class="referenceLink" title="Link to bibliographic citation" shape="rect">10</a>, <a href="#bib13" rel="references:#bib13" class="referenceLink" title="Link to bibliographic citation" shape="rect">13</a>, <a href="#bib14" rel="references:#bib14" class="referenceLink" title="Link to bibliographic citation" shape="rect">14</a>, <a href="#bib19" rel="references:#bib19" class="referenceLink" title="Link to bibliographic citation" shape="rect">19</a>, <a href="#bib20" rel="references:#bib20" class="referenceLink" title="Link to bibliographic citation" shape="rect">20</a> The presence of possible AD pathology in approximately 40% of the ADNI NC group is consistent with Li and colleagues'<a href="#bib21" rel="references:#bib21" class="referenceLink" title="Link to bibliographic citation" shape="rect">21</a> and Fagan and coauthors'<a href="#bib22" rel="references:#bib22" class="referenceLink" title="Link to bibliographic citation" shape="rect">22</a> findings that in the aging cognitively normal population there is a significant decrease in A&beta;<sub>1&ndash;42</sub> concentration and increased tau concentration in individuals older than 60 years, as compared with those younger than 60 years, and Gustafson and investigators'<a href="#bib23" rel="references:#bib23" class="referenceLink" title="Link to bibliographic citation" shape="rect">23</a> and Stomrud and researchers'<a href="#bib24" rel="references:#bib24" class="referenceLink" title="Link to bibliographic citation" shape="rect">24</a> reports that CSF A&beta;<sub>1&ndash;42</sub> concentration decreases are the most sensitive predictor of cognitive decline in elderly healthy subjects. Long-term follow-up of the ADNI cognitively normal individuals will be required to confirm that the CSF signature for AD accurately predicts AD pathology.</p></div><div class="para"><p>Indeed, our LR<sub>TAA</sub> model showed that the combination of A&beta;<sub>1&ndash;42</sub>, t-tau, and the number of <em>APO</em>&epsilon;<em>4</em> alleles provided the best delineation of mild AD from MCI and cognitively normal subjects in ADNI. An AD-like pathological CSF profile for A&beta;<sub>1&ndash;42</sub> and t-tau, the t-tau/A&beta;<sub>1&ndash;42</sub> ratio, was detected in 33 of the 37 ADNI MCI subjects who converted to a diagnosis of probable AD 1 year after their baseline CSF collection, whereas the addition of <em>APO</em>&epsilon;<em>4</em> as a covariate in the LR model did not improve on the prediction of conversion from MCI to probable AD. Further work is needed to develop additional panels of biomarkers, as well as to identify more genetic risk factors that will help distinguish AD from other neurodegenerative diseases associated with cognitive impairments.<a href="#bib25" rel="references:#bib25 #bib26 #bib27 #bib28" class="referenceLink" title="Link to bibliographic citations" shape="rect">25&ndash;28</a></p></div><div class="para"><p>Based on the data reported here from the first ADNI CSF biomarker study, we have confirmed and extended reports from other laboratories suggesting that CSF tau and A&beta; are the most informative AD biomarkers,<a href="#bib7" rel="references:#bib7 #bib8 #bib9 #bib10" class="referenceLink" title="Link to bibliographic citations" shape="rect">7&ndash;10</a>, <a href="#bib12" rel="references:#bib12 #bib13 #bib14 #bib15 #bib16" class="referenceLink" title="Link to bibliographic citations" shape="rect">12&ndash;16</a>, <a href="#bib19" rel="references:#bib19" class="referenceLink" title="Link to bibliographic citation" shape="rect">19</a>, <a href="#bib20" rel="references:#bib20" class="referenceLink" title="Link to bibliographic citation" shape="rect">20</a> and that there is a dose&ndash;response relation between CSF biomarkers and the number of <em>APO</em>&epsilon;<em>4</em> alleles,<a href="#bib29" rel="references:#bib29" class="referenceLink" title="Link to bibliographic citation" shape="rect">29</a> but the significance of our findings goes beyond this because our data are based on the use of validated CSF methods to measure tau and A&beta;<sub>1&ndash;42</sub> using CSF samples collected over a period of a year from 56 different ADNI performance sites. Thus, the results of these studies offer the promise that the methods used here can be exported to many different clinical laboratory settings to enable wider access to these AD biomarker tests by clinicians and researchers.</p></div></div><div class="section" id="sec1-ack-1"><div class="headingCont"><h3>Acknowledgements</h3></div><ol class="jumpList"><li><a href="#leftBorder" shape="rect">Top of page</a></li><li><a href="#abstract" shape="rect">Abstract</a></li><li><a href="#sec1-1" shape="rect">Subjects and Methods</a></li><li><a href="#sec1-2" shape="rect">Results</a></li><li><a href="#sec1-3" shape="rect">Discussion</a></li><li><a href="#sec1-ack-1" shape="rect">Acknowledgements</a></li><li><a href="#app1" shape="rect">Appendix</a></li><li><a href="#wol-references" shape="rect">References</a></li></ol><div class="para"><p>ADNI is supported by (AG024904), from the NIH (National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering), Foundation for the National Institutes of Health, Pfizer, Wyeth Research, Bristol-Myers Squibb, Eli Lilly &amp; Company, GlaxoSmithKline, Merck &amp; Company, AstraZeneca AB, Novartis Pharmaceuticals Corporation, Alzheimer's Association, Eisai Global Clinical Development, Elan Corporation plc, Forest Laboratories, and Institute for the Study of Aging, U.S. Food and Drug Administration. V.H.-Y.L. is supported by (AG10124) from the NIH (National Institute on Aging), Marian S. Ware Alzheimer Program, the John H. Ware 3rd Professorship for Alzheimer's Disease Research, and JQT is supported by the William Maul Measy-Truman G. Schnabel Jr MD Professorship of Geriatric Medicine and Gerontology (JQT).</p></div><div class="para"><p>We thank our ADNI colleagues for their contributions to the work summarized here. We thank Hugo Vanderstichele and Innogenetics NV Gent, Belguim for the generous donation of the INNO-BIA AlzBio 3 Research-use Immunoassay Kits used in this study. We also thank M. Figurski for help with the statistical analyses. We are grateful to Christopher M. Clark, A. Fagan, H. Arai, and H. Soares for providing aliquots of non-ADNI CSF samples to prepare the CSF quality-control pools used in the immunoassay system employed in this investigation. We thank D. Baldwin and the Molecular Diagnosis Genotyping Facility at the University of Pennsylvania Medical Center for provision of the ApoE&epsilon; genotyping data.</p></div></div><div class="appendix" id="app1"><div class="headingCont"><h3>Appendix</h3></div><ol class="jumpList"><li><a href="#leftBorder" shape="rect">Top of page</a></li><li><a href="#abstract" shape="rect">Abstract</a></li><li><a href="#sec1-1" shape="rect">Subjects and Methods</a></li><li><a href="#sec1-2" shape="rect">Results</a></li><li><a href="#sec1-3" shape="rect">Discussion</a></li><li><a href="#sec1-ack-1" shape="rect">Acknowledgements</a></li><li><a href="#app1" shape="rect">Appendix</a></li><li><a href="#wol-references" shape="rect">References</a></li></ol><div class="section" id="sec1-app-1"><div class="para"><p>Data used in preparing this article were produced by the Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core at the University of Pennsylvania or obtained from the ADNI database (<!--TODO: clickthrough URL--><a href="http://www.loni.ucla.edu/ADNI" title="Link to external resource: http://www.loni.ucla.edu/ADNI" shape="rect">www.loni.ucla.edu/ADNI</a>). Many ADNI investigators contributed to the design and implementation of ADNI or provided data but did not participate in the analysis of the data presented here or in the writing of this report. ADNI investigators include (complete listing available at <!--TODO: clickthrough URL--><a href="http://www.loni.ucla.edu\ADNI\Collaboration\ADNI_Manuscript_Citations.pdf" title="Link to external resource: http://www.loni.ucla.edu\ADNI\Collaboration\ADNI_Manuscript_Citations.pdf" shape="rect">www.loni.ucla.edu\ADNI\Collaboration\ADNI_Manuscript_Citations.pdf</a>).</p></div></div></div><div id="wol-references" class="bibliography"><div class="headingCont"><h3>References</h3></div><ol class="jumpList"><li><a href="#leftBorder" shape="rect">Top of page</a></li><li><a href="#abstract" shape="rect">Abstract</a></li><li><a href="#sec1-1" shape="rect">Subjects and Methods</a></li><li><a href="#sec1-2" shape="rect">Results</a></li><li><a href="#sec1-3" shape="rect">Discussion</a></li><li><a href="#sec1-ack-1" shape="rect">Acknowledgements</a></li><li><a href="#app1" shape="rect">Appendix</a></li><li><a href="#wol-references" shape="rect">References</a></li></ol><ul class="custom"><li id="bib1"><span class="bullet">1</span><div class="text"><cite id="cit1">  <span class="author">Forman MS</span>, <span class="author">Trojanowski JQ</span>, <span class="author">Lee VM-Y</span>. <span class="articleTitle">Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs</span>. <span class="journalTitle">Nat Med</span>  <span class="pubYear">2004</span>; <span class="vol">10</span>: <span class="pageFirst">1055</span>&ndash;<span class="pageLast">1063</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1038/nm1113" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=15459709" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2cXnvFyntbY%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000224245800034" shape="rect">Web of Science&reg; Times Cited: 156</a></li></ul></div></li><li id="bib2"><span class="bullet">2</span><div class="text"><cite id="cit2">  <span class="author">Selkoe DJ</span>. <span class="articleTitle">Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases</span>. <span class="journalTitle">Nat Cell Biol</span>  <span class="pubYear">2004</span>; <span class="vol">6</span>: <span class="pageFirst">1054</span>&ndash;<span class="pageLast">1061</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1038/ncb1104-1054" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=15516999" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2cXptFent7s%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000224816700010" shape="rect">Web of Science&reg; Times Cited: 168</a></li></ul></div></li><li id="bib3"><span class="bullet">3</span><div class="text"><cite id="cit3">  <span class="author">Skovronsky DM</span>, <span class="author">Lee VM-Y</span>, <span class="author">Trojanowski JQ</span>: <span class="articleTitle">Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications</span>. <span class="journalTitle">Annu Rev Pathol Mech Dis</span>  <span class="pubYear">2006</span>; <span class="vol">1</span>: <span class="pageFirst">151</span>&ndash;<span class="pageLast">170</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1146/annurev.pathol.1.110304.100113" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=18039111" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD28XktVOitbo%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000245565500006" shape="rect">Web of Science&reg; Times Cited: 52</a></li></ul></div></li><li id="bib4"><span class="bullet">4</span><div class="text"><cite id="cit4">  <span class="author">Forman MS</span>, <span class="author">Farmer J</span>, <span class="author">Johnson JK</span>, et al: <span class="articleTitle">Frontotemporal dementia: clinicopathological correlations</span>. <span class="journalTitle">Ann Neurol</span>  <span class="pubYear">2006</span>; <span class="vol">59</span>: <span class="pageFirst">952</span>&ndash;<span class="pageLast">962</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="/doi/10.1002/ana.20873/abstract" shape="rect">Abstract</a></li><li><a href="/doi/10.1002/ana.20873/full" shape="rect">Full Article (HTML)</a></li><li><a href="/doi/10.1002/ana.20873/pdf" shape="rect">PDF(350K)</a></li><li><a href="/doi/10.1002/ana.20873/references" shape="rect">References</a></li></ul></div></div></li><li id="bib5"><span class="bullet">5</span><div class="text"><cite id="cit5">  <span class="articleTitle">Consensus report of the Working Group on: Biological Markers of Alzheimer's Disease</span>. <span class="groupName">The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association</span> and the <span class="groupName">National Institute on Aging Working Group</span>. <span class="journalTitle">Neurobiol Aging</span>  <span class="pubYear">1998</span>; <span class="vol">19</span>: <span class="pageFirst">109</span>&ndash;<span class="pageLast">116</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/S0197-4580(98)00022-0" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=9558143" shape="rect">PubMed</a></li></ul></div></li><li id="bib6"><span class="bullet">6</span><div class="text"><cite id="cit6">  <span class="author">Frank RA</span>, <span class="author">Galasko D</span>, <span class="author">Hampel H</span>, et al: <span class="articleTitle">Biological markers for therapeutic trials in Alzheimer's disease&mdash;proceedings of the Biological Measures Working Group: NIA Initiative on Neuroimaging in Alzheimer's Disease</span>. <span class="journalTitle">Neurobiol Aging</span>  <span class="pubYear">2003</span>; <span class="vol">24</span>: <span class="pageFirst">521</span>&ndash;<span class="pageLast">536</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/S0197-4580(03)00002-2" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12714109" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000182799900001" shape="rect">Web of Science&reg; Times Cited: 98</a></li></ul></div></li><li id="bib7"><span class="bullet">7</span><div class="text"><cite id="cit7">  <span class="author">Shaw LM</span>, <span class="author">Korecka M</span>, <span class="author">Clark CM</span>, et al. <span class="articleTitle">Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics</span>. <span class="journalTitle">Nat Rev Drug Dis</span>  <span class="pubYear">2007</span>; <span class="vol">6</span>: <span class="pageFirst">295</span>&ndash;<span class="pageLast">303</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1038/nrd2176" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17347655" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2sXjs1SisL8%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000245359000014" shape="rect">Web of Science&reg; Times Cited: 49</a></li></ul></div></li><li id="bib8"><span class="bullet">8</span><div class="text"><cite id="cit8">  <span class="author">Sunderland T</span>, <span class="author">Linker G</span>, <span class="author">Mirza N</span>, et al. <span class="articleTitle">Decreased &beta;-amyloid1&ndash;42 and increased Tau levels in cerebrospinal fluid of patients with Alzheimer disease</span>. <span class="journalTitle">JAMA</span>  <span class="pubYear">2003</span>; <span class="vol">289</span>: <span class="pageFirst">2094</span>&ndash;<span class="pageLast">2103</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1001/jama.289.16.2094" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12709467" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000182374300025" shape="rect">Web of Science&reg; Times Cited: 155</a></li></ul></div></li><li id="bib9"><span class="bullet">9</span><div class="text"><cite id="cit9">  <span class="author">Blennow K</span>, <span class="author">Hampel H</span>. <span class="articleTitle">CSF markers for incipient Alzheimer's disease</span>. <span class="journalTitle">Lancet Neurology</span>  <span class="pubYear">2003</span>; <span class="vol">2</span>: <span class="pageFirst">605</span>&ndash;<span class="pageLast">613</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/S1474-4422(03)00530-1" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=14505582" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXotlGhsbg%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000185432000017" shape="rect">Web of Science&reg; Times Cited: 240</a></li></ul></div></li><li id="bib10"><span class="bullet">10</span><div class="text"><cite id="cit10">  <span class="author">Hansson O</span>, <span class="author">Zetterberg H</span>, <span class="author">Buchhave P</span>, et al. <span class="articleTitle">Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study</span>. <span class="journalTitle">Lancet Neurol</span>  <span class="pubYear">2006</span>; <span class="vol">5</span>: <span class="pageFirst">228</span>&ndash;<span class="pageLast">234</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/S1474-4422(06)70355-6" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=16488378" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD28XisF2qsbg%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000235632900017" shape="rect">Web of Science&reg; Times Cited: 209</a></li></ul></div></li><li id="bib11"><span class="bullet">11</span><div class="text"><cite id="cit11">  <span class="author">Mueller SG</span>, <span class="author">Weiner MW</span>, <span class="author">Thal LJ</span>, et al. <span class="articleTitle">Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI)</span>. <span class="journalTitle">Alzheimers Dement</span>  <span class="pubYear">2005</span>; <span class="vol">1</span>: <span class="pageFirst">55</span>&ndash;<span class="pageLast">66</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.jalz.2005.06.003" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17476317" shape="rect">PubMed</a></li></ul></div></li><li id="bib12"><span class="bullet">12</span><div class="text"><cite id="cit12">  <span class="author">Clark CM</span>, <span class="author">Xie S</span>, <span class="author">Chittams J</span>, et al. <span class="articleTitle">Cerebrospinal fluid tau and &beta;-Amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses</span>. <span class="journalTitle">Arch Neurol</span>  <span class="pubYear">2003</span>; <span class="vol">60</span>: <span class="pageFirst">1696</span>&ndash;<span class="pageLast">1702</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1001/archneur.60.12.1696" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=14676043" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000187178700004" shape="rect">Web of Science&reg; Times Cited: 80</a></li></ul></div></li><li id="bib13"><span class="bullet">13</span><div class="text"><cite id="cit13">  <span class="author">Clark CM</span>, <span class="author">Davatzikos C</span>, <span class="author">Borthakur A</span>, et al. <span class="articleTitle">Biomarkers for early detection of Alzheimer pathology</span>. <span class="journalTitle">NeuroSignals</span>  <span class="pubYear">2008</span>; <span class="vol">16</span>: <span class="pageFirst">11</span>&ndash;<span class="pageLast">18</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1159/000109754" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=18097155" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD1cXhs1Wns70%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000252706300002" shape="rect">Web of Science&reg; Times Cited: 12</a></li></ul></div></li><li id="bib14"><span class="bullet">14</span><div class="text"><cite id="cit14">  <span class="author">Clark CM</span>, <span class="author">Pratico D</span>, <span class="author">Shaw L</span>, et al. <span class="articleTitle">Biochemical biomarkers of late-life dementia</span>. <span class="journalTitle">Alzheimers Dement</span>  <span class="pubYear">2006</span>; <span class="vol">2</span>: <span class="pageFirst">287</span>&ndash;<span class="pageLast">293</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.jalz.2006.05.2347" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=19595902" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD28XhtlSms73L" shape="rect">ChemPort</a></li></ul></div></li><li id="bib15"><span class="bullet">15</span><div class="text"><cite id="cit15">  <span class="author">Olsson A</span>, <span class="author">Vanderstichele H</span>, <span class="author">Andreasen N</span>, et al. <span class="articleTitle">Simultaneous measurement of &beta;-amyloid<sub>(1-42)</sub>, total tau and phosphorylated tau (thr<sup>181</sup>) in cerebrospinal fluid by the xMAP technology</span>. <span class="journalTitle">Clin Chem</span>  <span class="pubYear">2005</span>; <span class="vol">51</span>: <span class="pageFirst">336</span>&ndash;<span class="pageLast">345</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1373/clinchem.2004.039347" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=15563479" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2MXhtVGhu7k%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000226717600010" shape="rect">Web of Science&reg; Times Cited: 55</a></li></ul></div></li><li id="bib16"><span class="bullet">16</span><div class="text"><cite id="cit16">  <span class="author">Vanderstichele H</span>, <span class="author">De Meyer G</span>, <span class="author">Engelborghs B</span>, et al. <span class="chapterTitle">Alzheimer's disease biomarkers: from concept to clinical utility</span>. In: <span class="editor">GalimbertiD</span>, <span class="editor">ScarpiniE</span>, eds. <span class="bookTitle">BioMarkers for early diagnosis of Alzheimer's disease</span>. Nova Science Publishers, <span class="publisherLocation">Haupauge, NY</span>. pp <span class="pageFirst">81</span>&ndash;<span class="pageLast">122</span>. <span class="pubYear">2008</span>.</cite></div></li><li id="bib17"><span class="bullet">17</span><div class="text"><cite id="cit17">  <span class="author">Reijn TSM</span>, <span class="author">Rikkert MO</span>, <span class="author">van Geel WJA</span>, et al. <span class="articleTitle">Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid &beta;42 and tau proteins</span>. <span class="journalTitle">Clin Chem</span>  <span class="pubYear">2007</span>; <span class="vol">53</span>: <span class="pageFirst">859</span>&ndash;<span class="pageLast">865</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1373/clinchem.2006.081679" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17395712" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2sXltFyqtrs%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000246248100009" shape="rect">Web of Science&reg; Times Cited: 7</a></li></ul></div></li><li id="bib18"><span class="bullet">18</span><div class="text"><cite id="cit18">  <span class="author">Roses AD</span>, <span class="author">Saunders AM</span>. <span class="articleTitle">ApoE, Alzheimer's disease, and recovery from brain stress</span>. <span class="journalTitle">Ann N Y Acad Sci</span>  <span class="pubYear">1997</span>; <span class="vol">826</span>: <span class="pageFirst">200</span>&ndash;<span class="pageLast">212</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="/doi/10.1111/j.1749-6632.1997.tb48471.x/abstract" shape="rect">Abstract</a></li><li><a href="/doi/10.1111/j.1749-6632.1997.tb48471.x/full" shape="rect">Full Article (HTML)</a></li><li><a href="/doi/10.1111/j.1749-6632.1997.tb48471.x/pdf" shape="rect">PDF(926K)</a></li><li><a href="/doi/10.1111/j.1749-6632.1997.tb48471.x/references" shape="rect">References</a></li></ul></div></div></li><li id="bib19"><span class="bullet">19</span><div class="text"><cite id="cit19">  <span class="author">de Leon, MJ</span>, <span class="author">De Santi S</span>, <span class="author">Zinkowski R</span>, et al. <span class="articleTitle">Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment</span>. <span class="journalTitle">Neurobiol Aging</span>  <span class="pubYear">2006</span>; <span class="vol">27</span>; <span class="pageFirst">394</span>&ndash;<span class="pageLast">401</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.neurobiolaging.2005.07.003" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=16125823" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD28XhtlCmsrg%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000235755400003" shape="rect">Web of Science&reg; Times Cited: 63</a></li></ul></div></li><li id="bib20"><span class="bullet">20</span><div class="text"><cite id="cit20">  <span class="author">Thal, LJ</span>, <span class="author">Kantarci K</span>, <span class="author">Reiman EM</span>, et al. <span class="articleTitle">The role of biomarkers in clinical trials for Alzheimer disease</span>. <span class="journalTitle">Alzheimer Dis Assoc Disord</span>  <span class="pubYear">2006</span>; <span class="vol">20</span>; <span class="pageFirst">6</span>&ndash;<span class="pageLast">15</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1097/01.wad.0000191420.61260.a8" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=16493230" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000235920300003" shape="rect">Web of Science&reg; Times Cited: 53</a></li></ul></div></li><li id="bib21"><span class="bullet">21</span><div class="text"><cite id="cit21">  <span class="author">Li G</span>, <span class="author">Sokal I</span>, <span class="author">Quinn JF</span>, et al. <span class="articleTitle">CSF tau/A&beta;42 ratio for increased risk of mild cognitive impairment: a followup study</span>. <span class="journalTitle">Neurology</span>  <span class="pubYear">2007</span>; <span class="vol">69</span>: <span class="pageFirst">631</span>&ndash;<span class="pageLast">639</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1212/01.wnl.0000267428.62582.aa" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17698783" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2sXos1anur4%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000248723600003" shape="rect">Web of Science&reg; Times Cited: 48</a></li></ul></div></li><li id="bib22"><span class="bullet">22</span><div class="text"><cite id="cit22">  <span class="author">Fagan AM</span>, <span class="author">Roe CM</span>, <span class="author">Xiong C</span>, et al. <span class="articleTitle">Cerebrospinal fluid tau/&beta;-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults</span>. <span class="journalTitle">Arch Neurol</span>  <span class="pubYear">2007</span>; <span class="vol">64</span>: <span class="pageFirst">343</span>&ndash;<span class="pageLast">349</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1001/archneur.64.3.noc60123" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17210801" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000244854600006" shape="rect">Web of Science&reg; Times Cited: 81</a></li></ul></div></li><li id="bib23"><span class="bullet">23</span><div class="text"><cite id="cit23">  <span class="author">Gustafson DR</span>, <span class="author">Skoog I</span>, <span class="author">Rosengren L</span>, et al. <span class="articleTitle">Cerebrospinal fluid &beta;-amyloid1&ndash;42 concentration may predict cognitive decline in older women</span>. <span class="journalTitle">J Neurol Neurosurg Psychiatry</span>  <span class="pubYear">2007</span>; <span class="vol">78</span>: <span class="pageFirst">461</span>&ndash;<span class="pageLast">464</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1136/jnnp.2006.100529" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17098843" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000245686000008" shape="rect">Web of Science&reg; Times Cited: 12</a></li></ul></div></li><li id="bib24"><span class="bullet">24</span><div class="text"><cite id="cit24">  <span class="author">Stomrud E</span>, <span class="author">Hansson O</span>, <span class="author">Blennow K</span>, et al. <span class="articleTitle">Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy controls</span>. <span class="journalTitle">Dement Geriatr Cogn Disor</span>  <span class="pubYear">2007</span>; <span class="vol">24</span>: <span class="pageFirst">118</span>&ndash;<span class="pageLast">124</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1159/000105017" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17622715" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2sXotVajs7g%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000247824400008" shape="rect">Web of Science&reg; Times Cited: 15</a></li></ul></div></li><li id="bib25"><span class="bullet">25</span><div class="text"><cite id="cit25">  <span class="author">Bian H</span>, <span class="author">Van Swieten JC</span>, <span class="author">Leight S</span>, et al. <span class="articleTitle">CSF biomarkers in frontotemporal lobar degeneration with known pathology</span>. <span class="journalTitle">Neurology</span>  <span class="pubYear">2008</span>; <span class="vol">70</span>: <span class="pageFirst">1827</span>&ndash;<span class="pageLast">1835</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1212/01.wnl.0000311445.21321.fc" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=18458217" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD1cXltlGjtro%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000256707200015" shape="rect">Web of Science&reg; Times Cited: 8</a></li></ul></div></li><li id="bib26"><span class="bullet">26</span><div class="text"><cite id="cit26">  <span class="author">Grossman M</span>, <span class="author">Farmer J</span>, <span class="author">Leight S</span>, et al. <span class="articleTitle">Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease</span>. <span class="journalTitle">Ann Neurol</span>  <span class="pubYear">2005</span>; <span class="vol">57</span>: <span class="pageFirst">721</span>&ndash;<span class="pageLast">729</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="/doi/10.1002/ana.20477/abstract" shape="rect">Abstract</a></li><li><a href="/doi/10.1002/ana.20477/full" shape="rect">Full Article (HTML)</a></li><li><a href="/doi/10.1002/ana.20477/pdf" shape="rect">PDF(260K)</a></li><li><a href="/doi/10.1002/ana.20477/references" shape="rect">References</a></li></ul></div></div></li><li id="bib27"><span class="bullet">27</span><div class="text"><cite id="cit27">  <span class="author">Kauwe JS</span>, <span class="author">Cruchaga C</span>, <span class="author">Mayo K</span>, et al. <span class="articleTitle">Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition</span>. <span class="journalTitle">Proc Natl Acad Sci U S A</span>  <span class="pubYear">2008</span>; <span class="vol">105</span>: <span class="pageFirst">8050</span>&ndash;<span class="pageLast">8054</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1073/pnas.0801227105" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=18541914" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000256781800028" shape="rect">Web of Science&reg; Times Cited: 8</a></li></ul></div></li><li id="bib28"><span class="bullet">28</span><div class="text"><cite id="cit28">  <span class="author">Zhang J</span>, <span class="author">Sokal I</span>, <span class="author">Peskind ER</span>, et al. <span class="articleTitle">CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases</span>. <span class="journalTitle">Am J Clin Pathol</span>  <span class="pubYear">2008</span>; <span class="vol">129</span>: <span class="pageFirst">526</span>&ndash;<span class="pageLast">529</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1309/W01Y0B808EMEH12L" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=18343778" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD1cXkvVeitr4%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000254127600002" shape="rect">Web of Science&reg; Times Cited: 12</a></li></ul></div></li><li id="bib29"><span class="bullet">29</span><div class="text"><cite id="cit29">  <span class="author">Galasko D</span>, <span class="author">Chang L</span>, <span class="author">Motter R</span>, et al. <span class="articleTitle">High cerebrospinal fluid tau and low A&beta;42 levels in the clinical diagnosis of Alzheimer disease in relation to apolipoprotein E genotype</span>. <span class="journalTitle">Arch Neurol</span>  <span class="pubYear">1998</span>; <span class="vol">55</span>: <span class="pageFirst">937</span>&ndash;<span class="pageLast">945</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1001/archneur.55.7.937" shape="rect">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=9678311" shape="rect">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:STN:280:DyaK1czktFCmsw%3D%3D" shape="rect">ChemPort</a>,</li><li><a href="/resolve/reference/ISI?id=000074852200006" shape="rect">Web of Science&reg; Times Cited: 226</a></li></ul></div></li></ul></div></div>          <div class="viewFullArticleAndPdf">             <div class="viewFullArticleAndPdfOptions">                                <a href="/doi/10.1002/ana.21610/pdf" title="Article in pdf format" id="bottomPdfLink" shape="rect">Get PDF (762K)</a>                             </div>         </div>                  <div id="relatedArticles">     <div class="sectionHeading">         <h3>More content like this</h3>     </div>     <span id="findArticlesHeading">Find more content:</span>     <ul class="findArticles"><li><a href="/advanced/search/results?articleDoi=10.1002%2Fana.21610&amp;scope=allContent&amp;start=1&amp;resultsPerPage=20" title="Link to articles like this" shape="rect">like this article</a></li></ul>     <span xmlns="http://www.w3.org/1999/xhtml" id="articlesWrittenByHeading">Find more content written by:</span><ul xmlns="http://www.w3.org/1999/xhtml" class="articlesWrittenBy"><li><a title="Link to more articles by Leslie M. Shaw" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Leslie M. Shaw&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Leslie M. Shaw</a></li><li><a title="Link to more articles by Hugo Vanderstichele" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Hugo Vanderstichele&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Hugo Vanderstichele</a></li><li><a title="Link to more articles by Malgorzata Knapik&#x2010;Czajka" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Malgorzata Knapik-Czajka&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Malgorzata Knapik-Czajka</a></li><li><a title="Link to more articles by Christopher M. Clark" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Christopher M. Clark&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Christopher M. Clark</a></li><li><a title="Link to more articles by Paul S. Aisen" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Paul S. Aisen&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Paul S. Aisen</a></li><li><a title="Link to more articles by Ronald C. Petersen" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Ronald C. Petersen&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Ronald C. Petersen</a></li><li><a title="Link to more articles by Kaj Blennow" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Kaj Blennow&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Kaj Blennow</a></li><li><a title="Link to more articles by Holly Soares" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Holly Soares&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Holly Soares</a></li><li><a title="Link to more articles by Adam Simon" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Adam Simon&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Adam Simon</a></li><li><a title="Link to more articles by Piotr Lewczuk" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Piotr Lewczuk&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Piotr Lewczuk</a></li><li><a title="Link to more articles by Robert Dean" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Robert Dean&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Robert Dean</a></li><li><a title="Link to more articles by Eric Siemers" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Eric Siemers&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Eric Siemers</a></li><li><a title="Link to more articles by William Potter" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;William Potter&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">William Potter</a></li><li><a title="Link to more articles by Virginia M.&#x2010;Y. Lee" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Virginia M.-Y. Lee&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">Virginia M.-Y. Lee</a></li><li><a title="Link to more articles by John Q. Trojanowski" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;John Q. Trojanowski&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">John Q. Trojanowski</a></li><li class="lastItem"><a title="Link to more articles by the present authors" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Leslie M. Shaw&quot; &quot;Hugo Vanderstichele&quot; &quot;Malgorzata Knapik-Czajka&quot; &quot;Christopher M. Clark&quot; &quot;Paul S. Aisen&quot; &quot;Ronald C. Petersen&quot; &quot;Kaj Blennow&quot; &quot;Holly Soares&quot; &quot;Adam Simon&quot; &quot;Piotr Lewczuk&quot; &quot;Robert Dean&quot; &quot;Eric Siemers&quot; &quot;William Potter&quot; &quot;Virginia M.-Y. Lee&quot; &quot;John Q. Trojanowski&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20" shape="rect">All Authors</a></li></ul> </div>         </div>  </div>                  <div id="footer">                     <div id="indexBottomLeftCorner"></div>                     <div id="indexBottomRightCorner"></div>                     <ul><li><a href="http://olabout.wiley.com.proxy.library.emory.edu/WileyCDA/Section/id-390001.html" shape="rect">ABOUT US</a></li><li><a href="http://onlinelibrary.custhelp.com/" shape="rect">HELP</a></li><li><a href="http://olabout.wiley.com.proxy.library.emory.edu/WileyCDA/Section/id-397203.html" shape="rect">CONTACT US</a></li><li><a href="http://olabout.wiley.com.proxy.library.emory.edu/WileyCDA/Section/id-390243.html" shape="rect">AGENTS</a></li><li><a href="http://olabout.wiley.com.proxy.library.emory.edu/WileyCDA/Section/id-390236.html" shape="rect">ADVERTISERS</a></li><li><a href="http://olabout.wiley.com.proxy.library.emory.edu/WileyCDA/Section/id-390242.html" shape="rect">MEDIA</a></li><li><a href="/privacyPolicy" shape="rect">PRIVACY</a></li><li><a href="/termsAndConditions" shape="rect">TERMS &amp; CONDITIONS</a></li><li><a href="/siteMap" shape="rect">SITE MAP</a></li></ul>                     <p>                         Copyright &copy; 1999-2010 John Wiley &amp; Sons, Inc. All Rights Reserved.                     </p>                 </div>                  <!-- SiteCatalyst code version: H.20.3. -->                 <script language="JavaScript" type="text/javascript" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/js/s_code_wileyonlinelibrary-production.js" xml:space="preserve"></script>                 <script language="JavaScript" type="text/javascript" xml:space="preserve"><!--
                /* You may give each page an identifying name, server, and channel on the next lines. */
                s.pageName=""
                s.server=""
                s.channel=""
                s.pageType=""
                s.prop1=""
                s.prop2=""
                s.prop3=""
                s.prop4=""
                s.prop5=""
                /* Conversion Variables */
                s.campaign=""
                s.state=""
                s.zip=""
                s.events=""
                s.products=""
                s.purchaseID=""
                s.eVar1=""
                s.eVar2=""
                s.eVar3=""
                s.eVar4=""
                s.eVar5=""
                /************* DO NOT ALTER ANYTHING BELOW THIS LINE ! **************/
                var s_code=s.t();if(s_code)document.write(s_code)//--></script>                 <script language="JavaScript" type="text/javascript" xml:space="preserve"><!--
                if(navigator.appVersion.indexOf('MSIE')>=0)document.write(unescape('%3C')+'\!-'+'-')
                //--></script>                 <noscript><a href="http://www.omniture.com" title="Web Analytics" shape="rect">
                    <img src="http://wileypublishing.112.2o7.net/b/ss/wileyonlinelibrary-development/1/H.20.3--NS/0?[AQB]&amp;cdp=3&amp;[AQE]" height="1" width="1" border="0" alt="" /></a></noscript>                 <!--/DO NOT REMOVE/-->                 <!-- End SiteCatalyst code version: H.20.3. -->                  <!-- Start Google Analytics -->                 <script type="text/javascript" xml:space="preserve">
                var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
                document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
                </script>                 <script type="text/javascript" xml:space="preserve">
                try {
                var pageTracker = _gat._getTracker("UA-11972776-3");
                pageTracker._trackPageview();
                } catch(err) {}</script>                 <!-- End Google Analytics -->        </div>     </div><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/js/jquery/jquery-1.4.2.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/js/jquery-ui-1.8/jquery.ui.widget.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/js/ol.widgets.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/js/jquery/jquery.cookie.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/js/jquery/jquery.bgiframe.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/js/jquery.easing-1.3.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/js/jquery.mousewheel.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/js/jquery.fancybox-1.3.1.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/js/wol.fancybox.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/js/wol.jquery.plugins.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com.proxy.library.emory.edu/js/wol.js" xml:space="preserve"></script></body></html>